

## Contents

Visual Overview .....	3
Abstract .....	5
Significance Statement.....	5
Table of Contents .....	5
1. Introduction .....	6
2. TNBC subtypes and their clinical characteristics .....	6
3. Biological characteristics of AR .....	9
3.1. Gene profile of the AR in BC subtypes .....	9
3.2. Structural and functional attributes of AR.....	10
4. A glimpse to AR in Prostate Cancer (PC) .....	12
5. The AR signaling pathway in the TNBC.....	13
6. AR targeting in TNBC .....	14
6.1. Monotherapy approaches .....	15
6.1.1. Bicalutamide .....	15
6.1.2. Enzalutamide .....	15
6.1.3. Abiraterone acetate .....	16
6.1.4. Seviteronel (VT-464) .....	16
6.2. Combination therapy .....	17
6.2.1. Combination of CDK4/6 and AR inhibitors .....	17
6.2.2. Combination of P13k and AR inhibitors .....	18
6.3. Novel AR inhibitors .....	18
6.3.1. LBD targeting using Next-generation AR inhibitors.....	18
6.3.2. Chaperone Inhibitors.....	19
6.3.3. Selective AR modulators .....	20
7. Genome editing against AR <sup>+</sup> cells, CRISPR/cas9 enters the scene .....	21
8. Overcoming drug resistance in TNBC by nanotechnology .....	23
9. Conclusions and future perspectives.....	23
Acknolegment.....	25
Funding.....	25
Ethical statement.....	25
Authorship Contributions .....	25

Footnotes .....	25
References.....	25
Figure Legends .....	38

## Visual Overview

# Newly Developed Targeted Therapies Against Androgen Receptor in Triple-Negative Breast Cancer: A Review

Edris Choupani<sup>1</sup>, Mohammad Mahmoudi Gomari<sup>1</sup>, Saeed Zanganeh<sup>2,3</sup>, Sherko Nasseri<sup>4</sup>, Kaveh Hajiallahverdipoor<sup>4</sup>, Neda Rostami<sup>5</sup>, Yaeren Hernandez<sup>6</sup>, Safa Najafi<sup>7</sup>, Neda Saraygord-Afshari<sup>1\*</sup>, Arshad Hoseini<sup>1\*</sup>

<sup>1</sup>Department of Biotechnology, Faculty of Allied Medicine, Iran University of Medical Science, Tehran, Iran

<sup>2</sup>Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical Sciences, Kerman, Iran

<sup>3</sup>Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran

<sup>4</sup>Department of Molecular Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

<sup>5</sup>Department of Chemical Engineering, Faculty of Engineering, Arak University, Iran

<sup>6</sup>Department of Cellular and Molecular Medicine, University of Arizona, Tucson, USA

<sup>7</sup>Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

## Targeted therapies against androgen receptor in TNBC

Corresponding Author#1: Dr. Neda Saraygord-Afshari, Assistant professor

Corresponding Author#2: Dr. Arshad Hosseini, Associate professor

Full postal address: Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences (IUMS), Shahid Hemmat Highway,

Tehran, 1449614535, IRAN

P.O Box: 14665-354

Tel: +98 (21) 86704668 and +98 (21) 88607944

Fax: +98 (21) 88052248

E-mail address: [Afshari.n@iums.ac.ir](mailto:Afshari.n@iums.ac.ir) AND [hoseini.a@iums.ac.ir](mailto:hoseini.a@iums.ac.ir)

Number of pages: 45

Number of figures: 5

Number of tables: 4

Word count of the Abstract: 181

### ABBREVIATIONS:

AATs, Androgen Ablation Therapies; AD, Androstenedione; ADT, Androgen Deprivation Therapy; AF, Activation Function; AKR1C3, Aldo-keto reductase family 1 member C3; AP, Androgen Precursors; AR, Androgen Receptor; ARE, Androgen Receptor Element; AR-FL, Androgen Receptor Full Length; AR-NTD, Androgen Receptor -N-terminal region; ARV, Androgen Receptor Variant; ATTs, AR-Targeting Therapies; BC, Breast Cancer; BCL11A, B-cell lymphoma/leukemia 11A; BF, Binding Function; BL, Basal-Like; CAS9, CRISPR - Associated Protein 9; CDK, Cyclin-Dependent Kinases; CE, Cryptic Exon; CoA, Co-activator; CRE, Cis-Regulatory Element; CRISPR/CAS9, Clustered Regularly Interspaced Short Palindromic Repeat- associated Protein 9; CRISPRi, CRISPR interference; CRPC, Castration Resistant Prostate Cancer; CSCs, Cancer Stem Cells; CTLA4, Cytotoxic T Lymphocyte-Associated Molecule-4; CYP17A1, Cytochrome P450 c17; DBD, DNA Binding Domain; DHEA, Dehydroepiandrosterone; DHT, Dihydrotestosterone; EGFR, Epidermal Growth Factor Receptor; EMT, Epithelial-Mesenchymal Transitions; Enza, Enzalutamide; ER, Estrogen Receptor; Er $\alpha$ , Estrogen Receptor- $\alpha$ ; Er $\beta$ , Estrogen Receptor- $\beta$ ; GC, Gemcitabine and Carboplatin; GT, Gemcitabine and Paclitaxel; GCR, Glucocorticoid Receptor; HBP, Hormone Binding Pocket; HDAC1/2, Histone deacetylase 1 and 2; HER2, Human Epidermal Growth Factor Receptor 2; HNRNPA1, Heterogeneous Nuclear Ribonucleoprotein A1; HRPC, Hormone-Refractory Prostate Cancer; HSD3 $\beta$ 1, Human 3-beta-hydroxysteroid dehydrogenase/delta5-4 isomerase type 1; HSP90, Heat Shock Protein 90; IGF-1R, Insulin-Like Growth Factor-1 Receptor; IM, Immunomodulatory; IL2, Interleukin; JAK-STAT3, Janus Kinases- Signal Transducers and Activators of Transcription; LAR, luminal Androgen Receptor-like; LBD, ligand-Binding Domain; M, Mesenchymal; MABC, Molecular Apocrine BC; MET, The human gene, also known tyrosine-protein kinase Met; MSL, Mesenchymal Stem-like; mTOR, Mechanistic Target of Rapamycin; NBL, Non-Basal-Like; NGF, Nerve Growth Factor; NK, Natural killer; NR3C4, Nuclear Receptor Subfamily 3, Group C, Member 4; NTD, N-terminal domain; PC, Prostate Cancer; PI3-K, Phosphoinositide 3-kinase; PR, Progesterone Receptor; SARMs, Selective Androgen Receptor Modulators; T, Testosterone;

TALEN, Transcription Activator-Like Effector Nuclease; TAUs, Trans Activator Units; TBCRC, Translational BC Research Consortium; TNBC, Triple Negative Breast Cancer; TX, Taxotere and Xeloda; VM, Vascular Mimicry; WHO, World Health Organization; ZFN, Zinc-Finger Nucleases

## **Abstract**

Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15-20 percent of breast malignancies. Three principal characteristics of TNBC cells are 1) extreme aggressiveness, 2) absence of hormones, and 3) growth factor receptors. Due to the lack or poor expression of estrogen-receptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone-receptor (PR), TNBC is resistant to hormones and endocrine therapies. Consequently, chemotherapy is currently utilized as the primary approach against TNBC. Expression of androgen receptor (AR) in carcinoma cells has been observed in a subset of patients with TNBC; therefore, inhibiting androgen signaling pathways holds promise for TNBC targeting. The new AR inhibitors have opened up new therapy possibilities for BC patients carrying AR-positive TNBC cells. Our group provides a comprehensive review of the structure and function of the AR and clinical evidence for targeting the cell's nuclear receptor in TNBC. We updated AR agonists, inhibitors, and antagonists. We also presented a new era of genetic manipulating CRISPR/Cas9 and nanotechnology as state of the art approaches against AR to promote the efficiency of targeted therapy in TNBC.

## **Significance Statement**

The lack of effective treatment for TNBC is a health challenge. The main disadvantages of existing treatments are their side effects, due to their non-specific targeting. Molecular targeting of cellular receptors, such as AR, increased expression in malignant tissues significantly improving the survival rate of breast cancer patients.

## **Table of Contents**

**Table 1.** Molecular classification of breast cancer.

**Table 2.** Subtypes of TNBC based on gene expression.

**Table 3.** Current clinical trials targeting the AR-signaling pathway in prostate cancer.

**Table 4.** Recently completed and recruiting clinical trials targeting androgen, CDK4/6 and PI3K signaling in TNBC.

## 1. Introduction

According to the World Health Organization (WHO), in 2021, there were 2.3 million women diagnosed with BC and 685 000 deaths globally. This makes BC the most prevalent malignancy in women around the world ([Gomari et al., 2021](#); [Nigam, 2013](#); [WHO, 2021](#)). Heterogeneity, diverse molecular and clinical features are the hallmarks of BC, leading to the need for various drugs to control this type of cancer ([Shah et al., 2013](#)). TNBC is defined as any type of breast cancer that lacks the expression of the ER, PR, and HER2 genes. This makes treatment more challenging because most hormone therapies target one of the three receptors ([Qiu et al., 2021](#)). Because of its aggressive biological features and lack of effective therapeutic choices, compared to other subtypes of breast cancer, TNBC has been associated with a poor prognosis. As a result, the discovery of innovative TNBC therapeutics is critical. Recently, numerous investigations have revealed that additional types of hormone receptors, such as the androgen receptor, are expressed in TNBC ([Elghazawy et al., 2021](#); [Gerratana et al., 2018](#); [Sridhar et al., 2022](#); [Traina et al., 2018](#)).

The design and development of new generation androgen inhibitors for control and targeting of AR have raised hopes for effective targeting of AR-positive TNBC cells. AR-targeted drugs have been approved with positive outcomes in clinical trials for the treatment of TNBC patients ([Anestis et al., 2020](#); [Yuan et al., 2021](#)). Molecular and immunohistochemical analyses revealed that AR-expressing TNBC cases were efficiently targeted using AR inhibitors ([Liu et al., 2018](#)). The main focus of this review is the new promising targeted therapies against AR-positive (AR+) TNBC subtypes; focusing on monotherapy, combination therapy, CRISPR/Cas9 gene editing and nanotechnology.

## 2. TNBC subtypes and their clinical characteristics

BC is classified into four molecularly distinct subtypes based on genetic profile, treatment response, and disease prognosis ([Eroles et al., 2012](#)). These BC malignancy subtypes are distinguished as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2+) enriched and basal-like or triple-negative BC (TNBC) ([Ades et al., 2014](#); [Tsang & Tse, 2020](#)). Typically, these three biomarkers, including the estrogen receptor (ER), progesterone receptor (PR), and HER2-/neu, are the main indicators to examine the molecular category of BC. Ki-67 is a tumor grade predictor, which is sometimes included in BC classification ([Karangadan et al., 2016](#); [Nazari et al., 2021](#)) (Table 1).

TNBC malignancy was first introduced by Brenton et al. with an incidence rate between 12% to 20% ([Brenton et al., 2005](#); [Howard & Olopade, 2021](#); [Zimmer, 2021](#)). TNBC is the

most aggressive type BC with a high risk of recurrence and metastasis ([Qin et al., 2019](#)). As its nomenclature implies, the absence or poor expression of BC biomarkers PR, ER, and HER2/neu is commonly considered the main clinical characteristics of TNBC ([Afghahi et al., 2017](#)). The lack of expression of these biomarkers strongly correlates with poor clinical prognosis ([Elbaz et al., 2015](#)). ER, PR, and HER2 are related to drug resistance, and the high rate of cancer-associated death occurrence in TNBC patients; targeting BC cancer cells by employing these receptors has attracted attention in recent years ([Anders & Carey, 2008](#); [Dogan & Turnbull, 2012](#)). The latest available data showed that about 83% of the BC-related death belong to TNBC patients; however this subtype of BC only accounts for 15–20% of the BC malignancies ([Kim et al., 2014](#); [Wein & Loi, 2017](#)) (Figure 1).

Chemotherapy medications such as tamoxifen, paclitaxel, cisplatin, and anthracycline are the first prescribed treatments given for patients with TNBC. However, the effectiveness of chemotherapeutics intervention due to rapid early tumor progression and drug resistance was overshadowed in TNBC patients ([Afghahi et al., 2017](#); [Elbaz et al., 2015](#); [Jhan & Andrechek, 2017](#); [Kim et al., 2014](#); [NAJAFI et al., 2014](#); [Takai et al., 2016](#); [Wein & Loi, 2017](#)). Given the high heterogeneity of tumor cells in TNBC, many efforts have been made to develop effective diagnostic and therapeutic approaches to control this type of BC.

Among numerous available systems ([Abramson et al., 2015](#); [Gong et al., 2021](#); [Jiang et al., 2021](#); [Takai et al., 2016](#); [Weigman et al., 2012](#)), the model developed by Lehmann et al. is regarded in our investigation and has employed for TNBC classification ([Lehmann et al., 2011](#)). Gene expression analysis and clinicopathological variables help classify TNBC for accurate pathological diagnosis and therapy selection ([Bando et al., 2021](#)). The basic of the Lehmann model was gene expression profile and ontologies. In this model, TNBC was categorized into six distinct subtypes, including basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) (see Table 2 for their characteristic features) ([Abramson et al., 2015](#); [Lehmann et al., 2011](#)). Owing to the intricacy of the many histological landscapes in tumor tissues, in the second investigation, Lehmann and et al employed histopathological quantification and laser-capture microdissection to demonstrate that IM and MSL transcripts were provided by infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, they refined TNBC molecular subtypes from six into four tumor-specific subtypes (BL1, BL2, M and LAR) (see Figure 1 for their incidence rates) ([Lehmann et al., 2016](#)).

Both BL1 and BL2 subtypes are distinguished by mutation appearance in BC genes 1 and 2 (BRCA1 and BRCA2). The BRCA1 and BRCA2 are the two known BC susceptibility genes

that are actively involved in the sensitivity of the malignant cells to platinum-based chemotherapies ([Dréan et al., 2017](#)). Investigation demonstrated that inhibition of BCL11A (B-cell lymphoma/leukemia 11A) and HDAC1/2 (Histone deacetylase 1 and 2) efficiently induced BL cells to transform into luminal A cells and enhanced ER expression, resulting in enhanced sensitivity to tamoxifen. In breast cancer patients, high levels of BCL11A and HDAC1/2 expression were associated with a poor prognosis. These findings highlight systems that regulate breast cancer morphologies and offer the possibility of reprogramming basal-like breast cancer cells in order to increase their targetability ([Choi et al., 2022](#)).

The hallmark characteristic of the mesenchymal and mesenchymal stem-like subtypes are enrichment of genes involved in growth factor-related signaling pathways that trigger epithelial-mesenchymal transitions (EMT). This latter characteristic makes these two BC subtypes sensitive to EMT inhibitors ([Hill et al., 2019](#)). The capacity to develop vascular-like networks, known as vascular mimicry (VM), is another feature of the mesenchymal-TNBC subtype that is known to cause metastatic spread ([Liu et al., 2013](#)). Furthermore, several evidences suggest that the aggressive character of mesenchymal-TNBC, which correlates with the presence of cancer stem cells (CSCs), demonstrates a distinct ability for self-renewal, tumor initiation, and resistance to typical cancer therapy ([O'Connor et al., 2018](#)). Moreover, it has been observed that the EMT program and CSC state are tightly linked in numerous carcinomas and are related with treatment failure, metastasis, and cancer relapse ([Hill et al., 2019](#)).

LAR subtype accounts for about 16% of TNBC ([Lehmann et al., 2016](#)). The remarkable trait of LAR subtype is a unique gene profile that makes cancer cells sensitive to hormone-based therapeutics, particularly regime containing AR-targeting agents ([Lehmann et al., 2011](#); [Lehmann et al., 2016](#); [Masuda et al., 2013](#)) (Figure 1). Although AR expression is not restricted to the LAR subtype, this nuclear receptor expression increased in the TNBC subtype. The LAR subtype was sometimes classified with the non-basal-like (NBL) TNBC; similar to the NBL subtype, they do not express basal-like markers. In comparison to the other TNBC subtypes, the LAR subtype was accompanied by a low pathological grade of malignancy and was more potent for metastasis to the lymph nodes and bone marrow ([Caiazza et al., 2016](#)). Regarding the characteristic features of the LAR subtype, this type of TNBC was in the spotlight of the prognosis optimization and treatment development programs ([Bratthauer et al., 2002](#); [Dogra et al., 2020](#); [Gao, 2010](#); [Gerratana et al., 2015](#)).



### 3. Biological characteristics of AR

The AR, also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a steroid hormone receptor ([Song et al., 2021](#)). Steroid hormones interact with four different kinds of hormone-receptors including glucocorticoid receptor (GCR), estrogen receptor- $\alpha$  (Er $\alpha$ ), estrogen receptor- $\beta$  (Er $\beta$ ), and AR ([Norman et al., 2004](#)). Steroid hormone receptors act as ligand-activated intracellular transcription factors; hence, it is considered for its gene regulatory capabilities. Depending on the type of signaling pathway stimulation, the steroid hormone receptors may have either or both positive and negative gene regulation activities to repress or trigger cellular processes such as proliferation, migration, and apoptosis ([Ahn et al., 2016](#); [Bonotto et al., 2014](#); [Gerratana et al., 2015](#); [Pietri et al., 2016](#); [Shah et al., 2013](#)).

#### 3.1. Gene profile of the AR in BC subtypes

The AR is a frequently occurring theragnostic BC marker expressed in 70% to 90% of all types of breast malignancies and is even more abundant than ER or PR ([Collins et al., 2011](#); [Niemeier et al., 2010](#)). The AR can be detected in two different subpopulations of mammary epithelial cells: invasive metaplastic apocrine carcinomas and luminal epithelial cells. However, the expression of the AR has markedly varied between these two subpopulations ([Rahim & O'Regan, 2017](#)). Molecular apocrine BC (MABC) is a BC subtype that is very similar to the LAR subtype; hence both are associated with a uniform expression in the metaplastic ER-/PR- apocrine cells. These cells are the most common cell population of the breast tissue (especially the fibrocystic ones).

In contrast, the luminal epithelial cells typically lack apocrine differentiation. The AR expression is not uniform; only 5% to 30% of this type of mammary epithelial cell content may contain AR. In these cells the AR is often co-expressed with ER and PR ([Rahim & O'Regan, 2017](#)). It should be noted that the tumor originated from two different subpopulations of mammary epithelial cells, causing two distinct neoplasms with different morphology and molecular signatures, even if they are identical in the expression of AR. This fact describes the different efficacy of the AR-based targeted therapies in these two subpopulations with two other AR-related regulatory mechanisms and expression levels. Therefore, the therapeutic response against AR-base targeted therapies is more dependent on the histological origin of the BC tumors (either molecular apocrine tumors or luminal epithelial abnormalities) ([Bratthauer et al., 2002](#); [Safarpour et al., 2014](#)).

### 3.2. Structural and functional attributes of AR

The AR is a nuclear receptor with a dynamic nucleocytoplasmic localization that acts as an intermediate for the cellular responses to the androgenic hormones ([Nguyen et al., 2009](#)). Like any other nuclear receptor, the AR is primarily a DNA-binding transcription factor, that is in the nucleus and can directly interact with DNA, mediating a range of DNA-binding-dependent signaling pathways ([Gao, 2010](#)). In physiologic conditions and the absence of the androgens, the free form of AR, which is transcriptionally inactive, is localized to the cytoplasm. However, upon binding an androgen molecule, it was translocated into the nucleus, where it can induce the expression of a specific set of AR-related genes. On the other hand, the cytoplasmic concentration of free AR are under control; hence cytoplasmic depletion of the AR acts as a signal that modulates the export of the nuclear AR from the nucleolus to the cytoplasm ([Nguyen et al., 2009](#)).

The AR gene is located on chromosome X (locus: Xq11–12); see Figure 2. This gene encodes eight exons, translated into a full-length protein of 920 amino acids and a molecular weight of 110 kDa. The AR full-length protein consists of four distinct functional and/or structural domains, including (i) NTD (N-terminal domain), (ii) DBD (DNA binding domain), also known as the central domain, (iii) a hinge region, and (iv) LBD (ligand-binding domain) see Figure 3 ([Anestis et al., 2015](#)). The N-C terminals interaction was a crucial requirement for AR activity. This interaction activates some of the binding domains for different ligands and is known as AR self-transactivation ([Monaghan & McEwan, 2016](#)).

The AR's primary functions serve as a DNA-binding transcription factor-mediated by the AR-NTD (amino acids 1-559). The AR-NTD is a sizeable regulatory domain composed of several more specific functional subdomains that do not adopt a well-defined independent 3D structure; therefore, they are not structurally well-separated. A number of the AR-NTD functional subdomains serve as binding sites for transcription factors, while others bind to the transcription co-factors. These subdomains actively regulate the expression of the genes involved in initiating the upstream signaling pathways linked to the AR ([Anestis et al., 2015](#); [Reid et al., 2003](#)). The AR-NTD is critical for AR transactivation. Most AR transactivation function is mediated by the AR-NTD's activation function subdomain-1 (also known as AR-AF-1) ([Zhao et al., 2002](#)). The AR-AF-1 is composed of two main transactivator units (TAUs), i.e., the TAU-1 and -5. The TAU-1 (amino acids 141-338) functions as a ligand-dependent transactivator, while the TAU-5 (amino acids 380-529) acts as a ligand-independent transactivator. Another distinguishable part of the AR-NTD is its flexible five-amino acid

motif (aminoacids 23-27, ) which is necessary for the AR's N-C terminals interaction. This flexible motif is also known as the FxxLF motif ([Monaghan & McEwan, 2016](#)). Considering the determinative crucial role of the AR-NTD in the AR activities, it is not surprising that mutations located in this region are responsible for most of the AR-related pathogenesis ([Chandrasekar et al., 2015](#); [Gottlieb et al., 2012](#); [Meakin & Clifton, 2019](#); [Mohler et al., 2012](#)). For example, in 2012, Gottlieb et al. described that about 30% of AR receptor mutations linked with PCare mapped to the AR-NTD ([Gottlieb et al., 2012](#)).

The central AR-DBD (amino acids 555-636) is a structurally well-defined region between the AR-NTD and the AR-hinge. Similar to other DBDs, the AR-DBD is responsible for DNA recognition. The AR-DBD is a highly conserved segment of the AR and is composed of two zinc-finger structural motifs (amino acids 560-580 and 596-620). Each motif consists of an  $\alpha$ -helix (D-box and P-box) primarily composed of hydrophobic amino acids (see Figure 3). The D-box (amino acids 560-580 and 596-620) is required for AR dimerization, while P-box (amino acid residues 577–581) is essential for recognizing the DNA-binding elements in the transcription factor motifs, enhancer regions, and promoters of the downstream-regulated genes linked to the AR ([Monaghan & McEwan, 2016](#); [Radaeva et al., 2021](#)). Evidence indicated that central roles in the AR-NTD are involved in modulating AR-DBD functions; this revealed an intra-domain functional dependency in the AR ([Brodie & McEwan, 2005](#)). Like AR-NTD, mutations occurring in the AR-DBD were also accompanied by several diseases and abnormalities, such as complete androgen insensitivity syndrome (CAIS) ([Chauhan et al., 2018](#)).

The AR-hinge region (amino acids 629–670) is a flexible segment between the AR-DBD and -CTD. This segment plays a vital role in the translocation of the AR molecule from the cytoplasm into the nucleus and vice versa. The AR-hinge region function is modulated by post-translationally modifications on the AR-RKLKKL motif, which sequence are located from amino acids 629-644. The AR-hinge region was responsible for the integration of the signals that are from different pathways. Mutations occurring in the AR-hinge region were also accompanied by several abnormalities, such as castrate-resistant (CR) disease ([Clinckemalie et al., 2012](#); [Haelens et al., 2007](#); [Monaghan & McEwan, 2016](#)).

The multifunctional AR-CTD (amino acids 673–918) is crucial for interaction and recognizing the androgenic hormones, it is known as the AR's main ligand-binding domain (LBD). The AR-LBD is the main target of androgen and anti-androgen therapies and is of great interest to clinical pharmacologists. AR-LBD (amino acids 669–900) has a well-defined 3D structure composed of twelve  $\alpha$ -helices and four  $\beta$ -sheets. In parallel with the AR-AF-1, which is located

in the AR-NTD, the AR-CTD also contains an activation function segment known as AR-CTD's activation function subdomain-2 (also known as AR-AF-2). This region located on the surface area of the AR-CTD 3D structure actively promoted the AR's N-C terminals cross-talk. The binding function 3 (BF-3) was the other main surface pocket of the AR-CTD. It is believed that the AR-BF-3 segment is involved in the allosteric regulation of the AF-2 function via its binding affinity for several agonists and antagonists. The most central subdomain of the AR-LBD is its hormone binding pocket (HBP). The AR-HBP comprises hydrophobic residues that can anchor specific ligands by a strong network of hydrophobic interactions and hydrogen bonds ([Anestis et al., 2015](#); [Caiazza et al., 2016](#); [Estébanez-Perpiñá et al., 2007](#); [Li et al., 2006](#); [Monaghan & McEwan, 2016](#)). Like the other AR domains, mutations in the AR-CTD can also lead to various diseases and abnormalities, including many types of cancers. Some AR-CTD mutations may also lead to resistance against the anti-androgens therapies ([Monaghan & McEwan, 2016](#)).

Researchers have shown that many AR-related mutations and abnormalities were involved in the pathogenesis and progression of TNBC. Many TN cell lines (for example, HCC3153, HCC1937, HCC1395, SUM149PT, SUM1315M02, and MDA-MB-436) have been used for *ex vivo* evaluation of the AR-related abnormalities. For example, Tilley et al. used the AR<sup>+</sup> TNBC (MDA-MB-453 cell line) to show that androgens modulate essential biological mechanisms, such as cell proliferation ([Nguyen et al., 2009](#)). The function of androgens in tumor formation and proliferation has also been demonstrated with research on other cell lines. In both the MFM223 and SUM185PE cell lines, a significant decrease in colony formation in culture was reported when AR was interrupted by siRNA ([Lehmann et al., 2011](#)).

Research using the MDA-MB-453 cell line indicates that AR signaling may play a role in the development of ER-negative BC cells that have a molecular apocrine phenotype. MDA-MB-453 demonstrates a molecular apocrine differentiation expressed as a mutated type of AR that occurs following Q865H mutation. This mutant has a diminished sensitivity to 5- $\alpha$ -dihydrotestosterone (DHT) and does not react to AR antagonists or non-androgenic ligands ([Moore et al., 2012](#)). These findings all indicate that androgens in TNBC cell lines can excite proliferation.

#### **4. A glimpse to AR in Prostate Cancer (PC)**

As with breast cancer, AR is an excellent target for treating prostate cancerous cells. PC is one of the most prevalent cancers in the men population ([Ban et al., 2021](#)). The incidence rate and mortality risk of PC are strongly age-dependent and are more pronounced in older

populations ([Rawla et al., 2019](#)). There is a continuous effort to introduce and develop safer and more efficient therapeutics against PC. Considering the crucial role of AR in the initiation and progression of PC, it has been in the spotlight of drug design and development programs over the past years. Many therapeutic agents for AR-directed targeting are currently under clinical trial or emerging into the market ([Lokeshwar et al., 2021](#); [Mohler et al., 2021](#); [Saranyutanon et al., 2020](#)).

The AR-directed therapies were classified into three main categories: androgen ablation therapies (AATs), androgen deprivation therapies (ADTs), and AR-targeting therapies (ATTs) ([Kim & Ryan, 2012](#)). Our focus in this study is on ATT's. Most of the AR antagonists (or anti-androgens) were directly bound to the LBD and inhibited the biological activity of androgens. Another strategy was the inhibition of androgen secretion; this was partly achieved by prostatectomy, which reduces the testosterone levels by 95 percent. However, androgen hormones will still produce via the adrenal glands ([Helsen et al., 2014](#)), which describes the growing demand for the development of AR-directed therapies.

Steroidal and non-steroidal anti-androgens are the two most potent anti-androgens inhibitors. Steroidal anti-androgens are capable bind to AR due to their structural similarity to androgens ([Ahmed et al., 2014](#)). Several steroidal anti-androgens such as; cyproterone acetate, dienogest, megestrol acetate, and chlormadinone acetate are used to inhibit AR in patients. Currently, several steroidal anti-androgens such as; cyproterone acetate, dienogest, megestrol acetate, and chlormadinone acetate are available to inhibit AR in patients. Cyproterone acetate is a member of steroidal anti-androgens that was widely used to treat PC. However, many of these steroidal anti-androgens are no longer recommended due to their insufficient efficacy and unacceptable level of side effects ([Narayanan, 2020](#)). Compared to steroidal anti-androgens, non-steroidal androgens were accompanied by fewer adverse side reactions. Among non-steroidal anti-androgens, flutamide, Bicalutamide, and nilutamide are considered first-generation non-steroidal anti-androgens, while Enzalutamide and Apalutamide are the potent second-generation therapeutics (Table 3).

### **5. The AR signaling pathway in the TNBC**

Unlike ER and PR, AR was expressed in most BC subtypes. At present, we know that AR is expressed in about 53% to 80% of all subtypes of the breast's cancerous cells. It was estimated that AR expressed in about 50% of the triple-negative tumor cells. The AR elevated expression levels in BC tumor cells are higher than ER or PR ([Gucalp & Traina, 2016](#); [Mina et al., 2017](#)). Compared to ER and PR, functions, dynamics, and regulation of AR in BC have not

been widely studied. In recent years, we learned much about the critical roles of AR in the pathogenesis and progression of various subtypes of BC; now, many more studies have focused on the functions and regulation of AR in BC ([McNamara et al., 2013](#)). Nevertheless, more information is needed to describe a robust correlation between AR expression levels and the BC theranostics. Especially regarding the bulk of contradictory evidence on the biological functions of androgens in TNBC ([Safarpour et al., 2014](#)).

On the other hand, there are positive and promising findings on the robustness of the AR targeting strategies in treating TNBC patients. Besides, several AR targeting agents were in the early stage of clinical trials ([Anestis et al., 2015](#)). The mechanisms by which AR signaling pathways affect breast carcinogenesis and its response to hormone therapies are not fully understood and need further investigation. We reviewed and discussed the recent findings on the efficacy of AR inhibition in treating TNBC. Much more attention was paid to the clinical data on the anti-androgen therapies among AR<sup>+</sup> TNBC.

## **6. AR targeting in TNBC**

The lack of known molecular targets in TNBC makes it ineffective against typical endocrine and HER2 inhibitor drugs. The development of next-generation anti-androgen drugs to treat PC has sparked an interest in scientists in using AR-inhibitors as a new treatment for TNBC, that can improve prognosis limit off-target effects ([Valerie N Barton et al., 2015](#)). In 1980, the first clinical trials of AR in BC were performed. In advanced BC, Flutamide was used as an oral anti-androgen with unknown estrogen, progesterone, and human epidermal growth factor (HER2) status. At that time, scientists did not demonstrate any significant behavior related to AR targeting during their research ([Gucalp & Traina, 2017](#); [Rampurwala et al., 2016](#)). In recent years, several clinical trials have shown the activity of anti-androgen therapy in the treatment of AR<sup>+</sup> TNBC (Table 4).

## 6.1. Monotherapy approaches

Given the potential role of AR in TNBC, many attempts have been made to design innovative therapeutic agents to inhibit its signaling pathways. Currently, several clinical trials are being conducted on various experimental monotherapy anti-androgens (Table 4).

### 6.1.1. Bicalutamide

The first registered clinical trial for targeting ARs was against advanced BC in the 1980s. After that, several investigations were conducted aimed at controlling AR pathways ([Perrault et al., 1988](#); [Zhao & He, 1988](#)). For example, [Gucalp et al.](#) in 2013 achieved significant success for anti-androgen therapy in BC patients. They revealed that Bicalutamide dramatically inhibited cancer cells ([Gucalp et al., 2013](#)). In addition, the Translational BC Research Consortium (TBCRC) clinical study reported a similarly successful experience to androgen inhibition in metastatic BC. This Phase II multi-center study assessed the regular oral Bicalutamide efficacy in both locally advanced (AR+, ER-/PR-) and metastatic BC ([Gucalp et al., 2012](#)). The FDA approved Bicalutamide as a non-steroidal, pure AR-antagonist anti-androgen for PC treatment ([Ismail et al., 2020](#)). To treat advanced cases of PC, Bicalutamide is used along with an analog of luteinizing hormone-releasing hormone. It is competitively bonded to AR to induce the accumulation of the inactivated AR and improve AR degradation ([Park et al., 2011](#)) (Figure 4). Besides PC, many studies showed that AR inhibition with Bicalutamide significantly diminishes proliferation and migration invasion and increases apoptosis in LAR and non-LAR TNBC subtypes, mesenchymal-like, mesenchymal stem-like, and basal-like 2 ([V. N. Barton et al., 2015](#); [Zhu et al., 2016](#)).

### 6.1.2. Enzalutamide

Enzalutamide (Enza), a second-generation AR antagonist, was supposed to suppress AR's nuclear translocation, its DNA binding, and co-activator mobilization (Figure 4). After receiving docetaxel, a multicenter placebo-controlled randomized clinical trial showed improved survival of patients with castration-resistant PC (CRPC). Enzalutamide was FDA-approved for patients with metastatic CRPC who had received docetaxel. It was demonstrated that the median PFS of Enzalutamide is longer than Bicalutamide ([Bernales et al., 2012](#); [Cochrane et al., 2012](#)).

Therapeutic outcomes of Enzalutamide have been examined in PR<sup>-</sup>/ER<sup>-</sup> BC preclinical models. Treatment with Enzalutamide in the AR<sup>+</sup>, ER<sup>-</sup> MDA-MB-453 cell line, and the xenograft

models led to increased apoptosis, reduced AR localization, and tumor growth inhibition. A similar effect has been shown in dihydrotestosterone-induced models of tumor growth ([Bernales et al., 2012](#); [Cochrane et al., 2012](#)). Enzalutamide influences the AR signaling pathway at several different levels. Enzalutamide's AR affinity is remarkably higher than Bicalutamide ([Cochrane et al., 2014](#)). Fatigue, nausea, and vomiting were the most frequent adverse reactions associated with Enzalutamide medication ([Elias et al., 2016](#); [Traina et al., 2013](#)).

### **6.1.3. Abiraterone acetate**

Abiraterone acetate is an androgen-directed therapy under evaluation to treat patients with AR<sup>+</sup> BC. It is a specific, potent and irreversible inhibitor of CYP17A1, the enzyme involved in the gonadal and adrenal glucocorticoids' biosynthesis; thus, it reduces both estrogen and androgen expression. Currently, this inhibitor is under clinical evaluation (phase II) in monotherapy form (NCT00755885; NCT01842321) and combined with AR antagonists (NCT01884285) ([Bonnefoi et al., 2016](#); [Gucalp & Traina, 2017](#); [Lyase](#)) (Table 4). UNICANCER, a French cooperative team, perfumed a multicenter clinical trial (Phase II) in women with inoperable locally advanced or metastatic AR<sup>+</sup> TNBC to define Abiraterone acetate's efficacy and safety along with prednisone ([Gucalp & Traina, 2016](#)). This study has hopeful outcomes in inhibiting TNBC.

For women suffering from AR<sup>+</sup> TNBC, oral administration of Abiraterone (1000 mg) was given daily, adding prednisone (5 mg) twice daily for preventing side effects associated with elevated mineralocorticoids levels ([Gerratana et al., 2018](#)). Given the action mechanism of Abiraterone acetate as a CYP17 inhibitor, it is reasonable to study its potential advantage in patients with AR+TNBC since it is expected that the levels of androgens are reduced due to the steroid synthesis pathway upstream inhibition ([Bonnefoi et al., 2016](#)) (Figure 4).

### **6.1.4. Seviteronel (VT-464)**

Seviteronel is a new androgen-directed agent for patients with PC. Also, it is under examination for treating patients with AR<sup>+</sup> TNBC. Seviteronel is an oral CYP17-L inhibitor, selective, as well as an AR antagonist reducing androgen production and hence may be potentially beneficial for AR TNBC patients ([Gucalp & Traina, 2016](#)) (Figure 4). Approximately Seviteronel showed 10-fold higher selectivity for inhibition of CYP17 lyase compared with CYP17 17-alpha hydroxylase. In addition to better select for CYP17 lyase than Abiraterone



([Rafferty et al., 2014](#)), it is a competitive antagonist to the mutations leading to resistance to Enzalutamide and Abiraterone ([Norris et al., 2017](#)).

Seviteronel inhibited the progression of several BC subtypes, both *in vivo* and *in-vitro*. Currently, Seviteronel completed Phase II clinical trial examination for men suffering from advanced CRPC as well as women and men suffering from advanced ER+ or TNBC (Table 4). The tolerability and safety of Seviteronel was confirmed for women with AR and ER RNBC and men with CRPC from the phase II trial ([Bardia et al., 2018](#); [Gupta et al., 2018](#)) (NCT02580448 and NCT02130700).

## 6.2. Combination therapy

According to clinical and pre-clinical studies, AR stimulates HER2+ BC or TNBC growth. Some combination therapies are directly engaged in the cell cycle's progression (CDK4/6 inhibitors), whereas others (MEK, PI3-K, and Ras inhibitors) are involved in regulating the most critical intracellular circuits leading to drug escape survival, proliferation, and invasiveness. Thus, the optimal results can be achieved using combination therapies, including AR antagonists and the mentioned pathway inhibitor ([Bianchini et al., 2016](#); [Robles et al., 2016](#)) (Table 4).

### 6.2.1. Combination of CDK4/6 and AR inhibitors

Studies demonstrated that, compared with mesenchymal and basal-like subtypes, LAR TNBC cell lines show particular susceptibility to CDK4/6 inhibitors, similar to ER+ MCF7 cell line ([Asghar et al., 2017](#)). As a CDK4/6 antagonist, Palbociclib inhibits cell proliferation by stopping the cell cycle in the G1-phase ([Fry et al., 2004](#)). Pre-clinical evidence suggests that Palbociclib's greatest activity in the luminal profile tumors with elevated Rb protein and cyclin D1 (CCND1) expression and p16 reduced expression. Rb protein is intact in AR<sup>+</sup> TNBC, a potent target for palbociclib. It has been shown that Palbociclib represses the cell growth in the MDA-MB-453 cell line (AR<sup>+</sup> TNBC) by decreasing Rb phosphorylation and preventing the thymidine incorporation into the DNA of RB<sup>+</sup> BC ([Finn et al., 2009](#)). Recent preclinical investigation has shown that Abemaciclib, an inhibitor of the cell cycle CDK4/6, in combination with seviteronel, an agent that targets both androgen biosynthesis and AR activity, demonstrated synergy in an AR<sup>+</sup> TNBC model compared to each drug alone ([Christenson et al., 2021](#)).

A limited number of studies have been conducted using CDK 4/6 in patients with metastatic TNBC. DeMichele et al. evaluated the effect of Palbociclib in thirty-seven patients (phase II

clinical trial) with RB1 wild-type metastatic BC, including 4 TNBC patients ([DeMichele et al., 2015](#)). Two clinical trials with identifier NCT03090165 and NCT02605486 on AR<sup>+</sup> TNBC patients are currently underway, including the combination of Palbociclib/Bicalutamide and Ribociclib/Bicalutamide, respectively. The results of these studies refer to the remarkable inhibiting of CDK4/6 and AR in treated patients ([Asghar et al., 2015](#); [Rampurwala et al., 2016](#)) (Table 4).

### **6.2.2. Combination of PI3k and AR inhibitors**

Among the introduced targets against BC, PI3K (phosphatidylinositol-3-kinase), which is known as a potent inhibitor ([Cuenca-López et al., 2014](#); [Koboldt et al., 2012](#)), and involved in Akt and mTOR (mechanistic target of rapamycin) pathways.

The rate of PIK3CA mutation among AR<sup>+</sup> BC is greater (~40%) compared with the AR- BC (4%) ([Lehmann et al., 2014](#)). PI3K inhibitors are promising to be effective for patients with TNBC. For example, Alpelisib, a PI3K inhibitor, has been fruitful for patients with HR+/HER2- BC according to the SOLAR-1 trial ([Norris et al., 2017](#)).

A pre-clinical study combined AR inhibitors therapy with PI3K antagonists demonstrated a synergistic apoptotic effect on the AR<sup>+</sup> TNBC cell line ([Cuenca-López et al., 2014](#)). In addition, the combination of AR inhibitors with PI3K/mTOR antagonists showed synergistic action on the TNBC AR<sup>+</sup> models ([Lehmann et al., 2014](#)). Based on the phase I outcomes of NCT01884285 and NCT03207529 clinical trials, which were performed to evaluate the effectiveness of the combination of AR inhibitors with PI3K/mTOR antagonists in patients with metastatic TNBC and AR<sup>+</sup>/PTEN low TNBC, respectively, it was determined that combination therapy significantly promoted the effectiveness of cancer therapy in BC.

### **6.3. Novel AR inhibitors**

LBD inhibitors, chaperone inhibitors and selective AR modulators are the newly developed inhibitors against AR-related signaling pathways.

#### **6.3.1. LBD targeting using Next-generation AR inhibitors**

For patients carrying LBD mutants, it was expected that targeting other domains could be helpful. Apalutamide (ARN-509), as the next-generation AR antagonist ([Clegg et al., 2012](#)), irreversibly and selectively binds to AR's ligand-binding domain with high affinity, resulting in AR's conformational change inhibiting the receptor complex's translocation to the nucleus, as a result, DNA binding and the concentration of AR accessible to bind androgen response

elements are reduced, eventually inhibiting AR-mediated transcription ([Clegg et al., 2012](#); [Isaacsson Velho et al., 2021](#); [Smith et al., 2016](#)). It was thought that the activity of Apalutamide was slightly higher compared with Enzalutamide, and it caused fewer seizurogenic side effects compared with Enzalutamide ([Smith et al., 2018](#)). When compared to bicalutamide, apalutamide has a 7–10-fold greater affinity for directly binding the AR ([Isaacsson Velho et al., 2021](#)). Pre-clinical results for ARN-509 indicated antitumor effects in the MDA-MB-453 cell line as AR<sup>+</sup>TNBC, but the research has not progressed past the pre-clinical level ([Clegg et al., 2012](#); [Speers et al., 2017](#)).

Darolutamide is another second-generation AR antagonist with a unique molecular structure that targets LBD ([Yu et al., 2019](#)). It exhibits more binding potency for wild-type AR compared with Enzalutamide. It inhibits translocation to the nucleus and does not exhibit agonist effect in case of AR overexpression, thus preventing or limiting possible seizurogenic effects ([Moilanen et al., 2013](#)). It was established as ODM-201 by Orion pharmaceuticals and further developed by Bayer ([Fizazi et al., 2019](#)).

Darolutamide inhibits AR variations such as W741L, T877A, H874Y, and F876L mutants, competitively binds to AR-LBD, and greatly reduces the development of enzalutamide-resistant prostate cancer cells in vivo ([Yu et al., 2019](#)). To date, no study has reported the use of this drug in breast cancer. Darolutamide was recently approved in the USA for the treatment of males with non-metastatic castration-resistant prostate cancer on the basis of favorable findings from the phase III ARAMIS study ([Fizazi et al., 2019](#); [Markham & Duggan, 2019](#)).

### 6.3.2. Chaperone Inhibitors

AR's normal activity depends on the binding of the ligand and the interaction between the chaperone proteins and co-activators. In the absence of the ligand, the AR is found in the cytoplasm and is bound to the Heat Shock Proteins (HSPs) as well as the rest of the inactive co-chaperones ([Osguthorpe & Hagler, 2011](#)). Molecular chaperones such as Hsp90 are engaged in protein folding, AR activation, transcription and trafficking in the AR signaling pathway. Exposed Hsp90 inhibitors lead to AR degradation in TNBC cells ([Agyeman et al., 2016](#)).

Onalespib (AT13387) and Ganetespib (STA-9090) are the inhibitors of Hsp90 and OGX-427. An inhibitor of hsp27 was developed in both BC and PC ([Proia et al., 2014](#); [Spiegelberg et al., 2020](#)). Hsp90 repression by Onalespib leads to proteasomal degradation and inhibition of several signal transduction pathways, such as the full-length AR (AR-FL) pathway ([Slovin et al., 2019](#)). In prostate cancer cell lines, onalespib decreases AR-FL protein in a concentration

and time-dependent manner, regardless of the AR-FL status (i.e., wild-type or mutant). Onalespib affects the splicing of at least 557 genes in prostate cancer cells, including AR, according to bioinformatic analysis of transcriptome-wide RNA sequencing data ([Ferraldeschi et al., 2016](#)). To date, no information has been reported on the use of Onalespib alone in breast cancer patients. However, the combination of this drug with Paclitaxel is being investigated in TNBC (phase Ib clinical trial) ([Wesolowski et al., 2019](#)).

Ganetespib, as a next-generation Hsp90 inhibitor, is a triazolone molecule with improved anticancer efficacy and safety profile compared to first-generation Hsp90 inhibitors. The interaction between Hsp90 and co-chaperone p23, which is necessary for effective chaperone function, is disrupted by ganetespib binding. Ganetespib inhibits the expression of HIF-1 target genes that contribute to the progression of TNBC ([Wesolowski et al., 2019](#)). Ganetespib induced the powerful and simultaneous disruption of the EGFR, AKT, and mTOR signaling pathways in TNBC cell lines, resulting in low nanomolar cytotoxicity values in vitro and significant tumor growth reduction in xenograft models ([Xiang et al., 2014](#)). Ganetespib significantly decreases the size of MDA-MB-231(TNBC cell)-derived xenograft tumors both alone and combined with several conventional chemotherapeutics ([Proia et al., 2014](#)). Also, Ganetespib suppressed the growth of MDA-MB-231 and MCF-7 xenografts, and in the BT-474 model led to tumor regression ([Friedland et al., 2014](#)).

### 6.3.3. Selective AR modulators

Since their discovery in the late 20th century ([Dalton et al., 1998](#)), selective androgen receptor modulators (SARMs) have been considered potential androgen therapies. SARMs were expected to radically transform the field of androgen therapy because they have the satisfaction and ability to extend androgen therapy to patients with BC without virilizing adverse effects ([Narayanan et al., 2014](#); [Negro-Vilar, 1999](#)). Compared to DMSO-treated tumors, SARMs suppress the proliferation of AR<sup>+</sup>TNBC and decrease tumor growth and weight by more than 90%. Through its effects on AR, SARM therapy prevents the intratumoral expression of genes and pathways that encourage the development of breast cancer ([Narayanan et al., 2014](#)). SARMs include a class of under developed drugs; contrary to the androgen synthesis inhibitors, they function as selective agonists of androgens and are promising as a possible treatment approach for BC. Enobosarm (GTx-024) is the most advanced drug in this category in clinical research it exhibits an agonistic activity preventing BC progression in certain patients. Pre-clinical outcomes demonstrated GTx-024 antitumor activity in AR<sup>+</sup> stable

expressions of MDA-MB-231 (TNBC) and MCF-7 (ER+) cell lines subcutaneously implanted in the nude mice ([Dalton et al., 2013](#)).

SARMs are small molecule compounds produced by chemical engineering, selectively used for various degrees of antagonist and agonist effects on AR in the different body tissues. SARMs' entrance to the cytoplasm is similar to androgens, and they can bind to the AR. The SARM-AR complex functions as a transcriptional regulator when translocated to the nucleus. It recruits the co-regulatory proteins and co-factors to modulate the AR complex's transcriptional response ([Christiansen et al., 2020](#); [Solomon et al., 2019](#)). Phase 1 clinical trial showed RAD140 a novel selective androgen receptor modulator, has an acceptable safety profile as well as preliminary indications of target engagement and anticancer efficacy in the treatment of AR<sup>+</sup>/ER<sup>+</sup>/HER2<sup>-</sup>-mBC (metastatic breast cancer) ([LoRusso et al., 2022](#)). Thus, it appears SARMs' signaling ability via AR depends on the way of interaction between specific conformations, AR's functional domains, the method of interaction between those domains and the cellular regulatory environment for targeting DNA expression. Since SARM-AR complexes show diverse conformations and particular AR expression patterns in tissues, transcriptional regulation, and co-regulatory protein levels; it can refer to tremendous diversity and capability of action.

### **7. Genome editing against AR<sup>+</sup> cells, CRISPR/cas9 enters the scene**

In recent years, many genome editing approaches have introduced rational changes in the genome, and CRISPR (clustered regularly interspaced short palindromic repeats) is one of them. Compared to other genome editing techniques, namely ZFN (Zinc-finger nucleases) and TALEN (transcription activator-like effector nuclease), the CRISPR/Cas9 method has more advantages in performance, repeatability and accuracy. CRISPR/Cas9 method has the potential to influence AR expression theoretically via two main pathways mediated by targeting the AR gene and mRNA modulation. At the DNA stage, AR silencing gene could be achieved by knocked out/in, and at the mRNA level, changes in splicing, expression, and polyadenylation can be considered (Figure 5). When the CRISPR system knocks out the AR gene, the cells are deprived of AR and become insensitive to androgens. Studies showed that partially knocked out the AR by the CRISPR system inhibits the growth and proliferation of LNCaP cancer cells ([Wei et al., 2018](#)). Androgen receptor enhancer activity like CRE (Cis-regulatory element), the CRISPR interference (CRISPRi) were to selectively inhibit annotated CREs and quantify the impact on AR-mediated gene expression ([Huang et al., 2021](#)). Another application of the CRISPR/CAS method could be regarded in Kounatido et al. They derived a valuable model

for the study of receptor splice variants, and introduced a stop codon into exon 5 of the AR locus by CRISPR/Cas9 mediating knock-in that leads to the CRISPR-derived FL-AR knockout CWR22Rv1 cell line which called CWR22Rv1-AR-EK ([Kounatidou et al., 2019](#)).

Resistance to AR-targeted treatments is a severe concern in PC and BC. Changes that occur at the genome or mRNA level in the AR gene cause different variants of the gene (Figure 5). For example, deletion of exons 5 to 7 in the AR-FL genome results in the AR-V12 (ARv567), which lacks the LBD domain at the protein level, and thus resistance to next-generation drugs such as Enzalutamide, which binds to the LBD domain. Variations due to different splicing and polyadenylation at the mRNA level create AR-V7 and AR-V9 variants. These variants lack the second LBD at the protein level and are insensitive to next-generation drugs that bind to the domain. Expression of AR-V1, AR-V7, and AR-V12 increased in hormone-refractory PC (HRPC) and metastasis, which increases resistance to Enzalutamide and androgen deprivation therapy, also induce an invasive adenocarcinoma and EMT *in-vivo* ([Radaeva et al., 2021](#); [Ware et al., 2014](#)). CRISPR can prevent exons deletion by targeting the desired sequence in the AR gene and modifying this sequence, as well as prevent the development of resistant variants by different splicing and polyhadilation at the mRNA level ([Yong et al., 2017](#)).

SF3B2 plays a crucial role in splicing AR-FL and creating AR-V7. Studies showed that different splicing due to overexpression of SF3B2 is one of the mechanisms of PC progression and resistance to treatment. These studies proposed SF3B2 as a therapeutic target candidate for the treatment of cancer patients ([Kawamura et al., 2019](#)). CRISPR technology could be a good option for treating cancer patients by targeting SF3B2 and preventing the development of resistant androgen receptor variants. Another study examed the role of the heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) as a splicing factor found that the factor played an important role in increasing AR-V7 expression ([Tietz & Dehm, 2020](#)). By knocking down HNRNPA1 in cancerous cells and thereby reducing AR-V7 expression, these cells lost resistance to Enzalutamide. CRISPR/Cas9 proved successful in targeting AR in PC. It is predicted that the same method will also work in TNBC, although studies in this area are limited.

## 8. Overcoming drug resistance in TNBC by nanotechnology

Despite many advances in well-known treatment protocols such as chemotherapy and radiation therapy ([Mahmoudi Gomari et al., 2021](#)), cancer therapy is still far from a favorable state. Nonspecific distribution, low drug concentrations at the tumor site, high toxicity, off-target activity, and drug resistance are the most common obstacles in the field of drug delivery against malignant cells. Therefore, developing efficient technologies for targeted therapy in cancer is a principal issue ([Misra et al., 2010](#)). In recent years, advances in nanotechnology have introduced new approaches for drug delivery against cancer cells ([Jin et al., 2020](#)). By designing diverse nanoparticles for targeted therapy, nanotechnology promises solutions to several current barriers against cancer. Nanoparticles are particles at the nanoscale (1-100 nm) composed of materials such as metals, polymers, and ceramics and have different morphologies depending on the fabrication method ([Aghamiri et al., 2019](#); [Rostami & Davarnejad, 2021](#); [Wang et al., 2008](#)). Nanoparticles have been considered in the treatment of BC, especially TNBC, due to their small size, high drug loading capacity, high circulating half-life, low systemic toxicity, efficient permeability to tumor tissue, and controlled release ([Thakur & Kutty, 2019](#)).

Liposomes are well-known nanoparticles about 400 nanometers in size. A commercial form of liposome containing doxorubicin is currently available for BC therapy ([Franco et al., 2018](#)). Daei et al. designed a liposome that efficiently targets TNBC. This liposome successfully was implemented to deliver doxorubicin and sorafenib ([Dai et al., 2014](#)). In another study, Andey et al. designed a liposome attached to estrogen derivatives and showed anti-cancer activity in mice with TNBC xenograft tumors ([Andey et al., 2015](#)). In a similar study, Erik et al. showed that antiandrogen gold nanoparticles bound an androgen receptor with 5- to 11-fold greater affinity than free antiandrogens, and per particle, bound androgen receptor with an affinity superior to endogenous androgens, allowing for further improved therapy effectiveness ([Dreaden et al., 2012](#)).

## 9. Conclusions and future perspectives

Many experimental treatments are being developed to conquer mechanisms that cause resistance to AR antagonists in prostate cancer. The function of the AR and its pathways is not well known in TNBC. However, experimental studies found that inhibition of AR activity in patients with AR<sup>+</sup>TNBC can be considered an option in BC therapy protocols. Early androgen signaling inhibitors were first studied as regular androgen deprivation therapy (ADT) for PC. Wong and Xie, in 2001, examined the correlation between androgen exposure and BC in rat

models. They demonstrated androgens inducing histological transformation, reversed with the androgen blocking agent flutamide. In many preclinical studies, it was confirmed that AR could be a druggable therapeutic target for BC patients, especially in ER<sup>-</sup>/PR<sup>-</sup>/AR<sup>+</sup> subtype inhibition of the AR pathway may be helpful against TNBC ([Ahn et al., 2016](#)).

Some of the most important reasons that Androgen receptors (ARs) inhibitor drugs have not been used as a targeted therapy for breast cancer patients, as much as in prostate cancer patients are listed below:

I: As a result of a lack of information on the signaling pathway and the role of ARs in breast cancer, no drugs have been developed to inhibit this receptor in the past. Nevertheless, in recent years, as our understanding of ARs and breast cancer has grown, numerous drugs have been designed and most are in the clinical trials stage. II: The standard ARs expression assay for prostate cancer is well known, however in breast cancer, there is no definitive method. III: After AR-directed therapy for prostate cancer, the predictive utility of ARs in tumor response has been clearly shown, however its predictive function in the treatment of TNBC is still unknown. IV: ARs antagonists are being studied in both preclinical and clinical study for treatment of TNBC, however, there is currently no reliable biomarker has been found to predict treatment efficacy ([Sridhar et al., 2022](#); [Witzel et al., 2019](#)).

Based on the reported data, it is proposed that the signaling cascades involved in AR-related pathways have fundamental roles in TNBC initiation and progression. For example, anti-AR, PI3K, and CDK4/6 exhibit high activity against the TNBC LAR subtype ([Lehmann et al., 2011](#)). Available evidence indicates that in AR<sup>+</sup> TNBC patients, the combinatorial targeting of the AR with CDK4/6 or PI3K pathways would be of clinical benefit ([Gucalp & Traina, 2016](#); [Lehmann et al., 2014](#)). The evaluation of combination therapy protocols such as anti-AR with CDK4/6, mTOR, P13k, and immune checkpoint inhibitors should be further examined to increase the effectiveness of the therapy. Targeting more than one signaling pathway involved in carcinogenesis seems to be promising provided that suitable targets are chosen and the most effective and less toxic combinations of agents are employed.

CRISPR and nanotechnology raise hopes for targeting cancerous cells in TNBC patients as two newly emerging approaches. Targeting different regions of the AR gene using the CRISPR system is a potential gene-editing method to control expression. Studies revealed that knocking out AR gene utilizing the CRISPR method attenuates cancer cell growth and proliferation ([Wei et al., 2018](#)). Different AR splicing variants that confer resistance to new drugs can be overridden by editing the AR genome in TNBC cells using CRISPR technology if tumor-specific delivery can be achieved.



The efficiency of TNBC therapy can be considerably improved by nanotechnology. In addition to enhancing drug toxicity, targeted therapy, timely drug release, nanoparticles may be utilized as CRISPR promotes genome editing accurately in TNBC models. Many studies have been performed on AR suppressors by nanoparticles in PC ([Lee et al., 2016](#); [Lee et al., 2012](#); [Yamamoto et al., 2015](#); [Zhang et al., 2017](#)). However, In the context of TNBCs, there has been no evaluation of nanoparticles suppressing the AR gene. Therefore, the use of nanocarriers for suppression and targeted therapy of AR in TNBC is warranted for future studies.

### **Acknowledgment**

We would like to express our great appreciation to professor Junxuan Lu from the Department of Pharmacology and Cancer Institute, Penn State, Hershey, Pennsylvania, USA, for his valuable and constructive suggestions during the planning and development of this research work. His willingness to give his time so generously has been very much appreciated.

### **Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Ethical statement**

This article does not contain any studies with human participants or animals performed by any of the authors.

### **Authorship Contributions**

*Participated in research design:* Edris Choupani, Safa Najafi, Neda Saraygord-Afshari, Arshad Hoseini

*Wrote or contributed to the writing of the manuscript:* Edris Choupani, Mohammad Mahmoudi Gomari, Saeed Zanganeh, Sherko Nasserli, Kaveh Haji-allahverdipoor, Neda Rostami, Yaeren Hernandez

### **Footnotes**

No author has an actual or perceived conflict of interest with the contents of this article.

### **References**

- Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015). Subtyping of triple-negative breast cancer: implications for therapy. *Cancer*, *121*(1), 8-16.
- Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., De Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014). Luminal B breast cancer: molecular

- characterization, clinical management, and future perspectives. *Journal of Clinical Oncology*, 32(25), 2794-2803.
- Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P.-J., Schackmann, E., Hartman, A.-R., & Ford, J. M. (2017). Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance. *Clinical Cancer Research*, 23(13), 3365-3370.
- Aghamiri, S., Jafarpour, A., Malekshahi, Z. V., Mahmoudi Gomari, M., & Negahdari, B. (2019). Targeting siRNA in colorectal cancer therapy: Nanotechnology comes into view. *Journal of Cellular Physiology*, 234(9), 14818-14827. <https://doi.org/https://doi.org/10.1002/jcp.28281>
- Agyeman, A. S., Jun, W. J., Proia, D. A., Kim, C. R., Skor, M. N., Kocherginsky, M., & Conzen, S. D. (2016). Hsp90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer. *Hormones and cancer*, 7(2), 114-126.
- Ahmed, A., Ali, S., & Sarkar, F. H. (2014). Advances in androgen receptor targeted therapy for prostate cancer. *Journal of cellular physiology*, 229(3), 271-276.
- Ahn, S. G., Kim, S. J., Kim, C., & Jeong, J. (2016). Molecular classification of triple-negative breast cancer. *Journal of breast cancer*, 19(3), 223-230.
- Al-Salama, Z. T. (2018). Apalutamide: first global approval. *Drugs*, 78(6), 699-705.
- Anders, C., & Carey, L. A. (2008). Understanding and treating triple-negative breast cancer. *Oncology (Williston Park, NY)*, 22(11), 1233.
- Andey, T., Sudhakar, G., Marepally, S., Patel, A., Banerjee, R., & Singh, M. (2015). Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. *Molecular pharmaceuticals*, 12(4), 1105-1120.
- Anestis, A., Karamouzis, M. V., Dalagiorgou, G., & Papavassiliou, A. G. (2015). Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? *Cancer treatment reviews*, 41(6), 547-553.
- Anestis, A., Zoi, I., Papavassiliou, A. G., & Karamouzis, M. V. (2020). Androgen receptor in breast cancer—clinical and preclinical research insights. *Molecules*, 25(2), 358.
- Asghar, U., Herrera-Abreu, M. T., Cutts, R., Babina, I., Pearson, A., & Turner, N. C. (2015). Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. In: American Society of Clinical Oncology.
- Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltneane, J., Lacap, J. A., Crocker, L., & Young, A. (2017). Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. *Clinical Cancer Research*, 23(18), 5561-5572.
- Ban, F., Leblanc, E., Cavga, A. D., Huang, C.-C. F., Flory, M. R., Zhang, F., Chang, M. E., Morin, H., Lallous, N., & Singh, K. (2021). Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. *Cancers*, 13(14), 3488.
- Bando, Y., Kobayashi, T., Miyakami, Y., Sumida, S., Kakimoto, T., Saijo, Y., & Uehara, H. (2021). Triple-negative breast cancer and basal-like subtype: Pathology and targeted therapy. *The Journal of Medical Investigation*, 68(3.4), 213-219.
- Bardia, A., Gucalp, A., DaCosta, N., Gabrail, N., Danso, M., Ali, H., Blackwell, K. L., Carey, L. A., Eisner, J. R., & Baskin-Bey, E. S. (2018). Phase I study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. *Breast cancer research and treatment*, 171(1), 111-120.

- Barton, V. N., D'Amato, N. C., Gordon, M. A., Lind, H. T., Spoelstra, N. S., Babbs, B. L., Heinz, R. E., Elias, A., Jedlicka, P., Jacobsen, B. M., & Richer, J. K. (2015). Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. *Mol Cancer Ther*, *14*(3), 769-778. <https://doi.org/10.1158/1535-7163.mct-14-0926>
- Barton, V. N., D'Amato, N. C., Gordon, M. A., Christenson, J. L., Elias, A., & Richer, J. K. (2015). Androgen receptor biology in triple negative breast cancer: a case for classification as AR+ or quadruple negative disease. *Hormones and cancer*, *6*(5), 206-213.
- Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., & Albarracin, C. (2017). Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase I trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. *JAMA oncology*, *3*(4), 509-515.
- Bastos, D. A., & Antonarakis, E. S. (2016). Galeterone for the treatment of advanced prostate cancer: the evidence to date. *Drug design, development and therapy*, *10*, 2289.
- Bernales, S., Guerrero, J., Gómez, F., Alfaro, I. E., & Protter, A. A. (2012). Effect of MDV3100, a novel androgen receptor signaling inhibitor, on cell proliferation and tumor size in an apocrine breast cancer xenograft model. In: American Society of Clinical Oncology.
- Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nature reviews Clinical oncology*, *13*(11), 674-690.
- Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'haridon, T., Cottu, P., Abadie-Lacourtoisie, S., & You, B. (2016). A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). *Annals of Oncology*, *27*(5), 812-818.
- Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A. M., Andretta, C., Mansutti, M., & Pisa, F. E. (2014). Measures of outcome in metastatic breast cancer: insights from a real-world scenario. *The oncologist*, *19*(6), 608-615.
- Bratthauer, G. L., Lininger, R. A., Man, Y.-g., & Tavassoli, F. A. (2002). Androgen and estrogen receptor mRNA status in apocrine carcinomas. *Diagnostic Molecular Pathology*, *11*(2), 113-118.
- Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? *Journal of clinical oncology*, *23*(29), 7350-7360.
- Brodie, J., & McEwan, I. J. (2005). Intra-domain communication between the N-terminal and DNA-binding domains of the androgen receptor: modulation of androgen response element DNA binding. *Journal of molecular endocrinology*, *34*(3), 603-615.
- Caiazza, F., Murray, A., Madden, S. F., Synnott, N. C., Ryan, E. J., O'Donovan, N., Crown, J., & Duffy, M. J. (2016). Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. *Endocrine-related cancer*, *23*(4), 323-334.
- Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015). Mechanisms of resistance in castration-resistant prostate cancer (CRPC). *Translational andrology and urology*, *4*(3), 365.
- Chauhan, P., Rani, A., Singh, S. K., & Rai, A. K. (2018). Complete androgen insensitivity syndrome due to mutations in the dna-binding domain of the human androgen receptor gene. *Sexual Development*, *12*(6), 269-274.

- Choi, S. R., Hwang, C. Y., Lee, J., & Cho, K.-H. (2022). Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability BCL11A–HDAC1/2 Regulate Tamoxifen Response in Breast Cancer. *Cancer research*, 82(2), 320-333.
- Christenson, J. L., O'Neill, K. I., Williams, M. M., Spoelstra, N. S., Jones, K. L., Trahan, G. D., Reese, J., Van Patten, E. T., Elias, A., & Eisner, J. R. (2021). Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer AR Antagonism Combined with Cell Cycle Inhibition in TNBC. *Molecular cancer therapeutics*, 20(6), 1062-1071.
- Christiansen, A. R., Lipshultz, L. I., Hotaling, J. M., & Pastuszak, A. W. (2020). Selective androgen receptor modulators: the future of androgen therapy? *Translational andrology and urology*, 9(Suppl 2), S135.
- Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., & Cai, L. (2012). ARN-509: a novel antiandrogen for prostate cancer treatment. *Cancer research*, 72(6), 1494-1503.
- Clinckemalie, L., Vanderschueren, D., Boonen, S., & Claessens, F. (2012). The hinge region in androgen receptor control. *Molecular and cellular endocrinology*, 358(1), 1-8.
- Cochrane, D., Bernales, S., Jacobsen, B., D'Amato, N., Guerrero, J., Gomez, F., Protter, A., Elias, A., & Richer, J. (2012). Abstract P2-14-02: Preclinical Evaluation of Enzalutamide in Breast Cancer Models. In: AACR.
- Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D'Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., & Guerrero, J. (2014). Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. *Breast Cancer Research*, 16(1), 1-19.
- Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011). Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. *Modern Pathology*, 24(7), 924-931.
- Cuenca-López, M. D., Montero, J. C., Morales, J. C., Prat, A., Pandiella, A., & Ocana, A. (2014). Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. *BMC cancer*, 14(1), 1-10.
- Dai, W., Yang, F., Ma, L., Fan, Y., He, B., He, Q., Wang, X., Zhang, H., & Zhang, Q. (2014). Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin  $\alpha 3$  in triple-negative breast cancer. *Biomaterials*, 35(20), 5347-5358.
- Dalton, J., Narayanan, R., & Steiner, M. (2013). Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer. In: AACR.
- Dalton, J. T., Mukherjee, A., Zhu, Z., Kirkovsky, L., & Miller, D. D. (1998). Discovery of nonsteroidal androgens. *Biochemical and biophysical research communications*, 244(1), 1-4.
- DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., & Colameco, C. (2015). CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. *Clinical Cancer Research*, 21(5), 995-1001.
- Dogan, B., & Turnbull, L. (2012). Imaging of triple-negative breast cancer. *Annals of Oncology*, 23, vi23-vi29.
- Dogra, A., Mehta, A., & Doval, D. C. (2020). Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different? *Journal of oncology*, 2020.
- Dole, E. J., & Holdsworth, M. T. (1997). Nilutamide: an antiandrogen for the treatment of prostate cancer. *Annals of Pharmacotherapy*, 31(1), 65-75.

- Dreaden, E. C., Gryder, B. E., Austin, L. A., Tene Defo, B. A., Hayden, S. C., Pi, M., Quarles, L. D., Oyelere, A. K., & El-Sayed, M. A. (2012). Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. *Bioconjugate chemistry*, 23(8), 1507-1512.
- Dréan, A., Williamson, C. T., Brough, R., Brandsma, I., Menon, M., Konde, A., Garcia-Murillas, I., Pemberton, H. N., Frankum, J., & Rafiq, R. (2017). Modeling therapy resistance in BRCA1/2-mutant cancers. *Molecular cancer therapeutics*, 16(9), 2022-2034.
- Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., & Thompson Jr, I. M. (1998). Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *New England Journal of Medicine*, 339(15), 1036-1042.
- Elbaz, M., Nasser, M. W., Ravi, J., Wani, N. A., Ahirwar, D. K., Zhao, H., Oghumu, S., Satoskar, A. R., Shilo, K., & Carson III, W. E. (2015). Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. *Molecular oncology*, 9(4), 906-919.
- Elghazawy, H., Bakkach, J., Helal, T., Aref, A. M., Kelany, M., Abdallah, L. E., Abdelbakey, F. S., Ali, D., Ali, D. Z., & Ahmed, M. O. (2021). Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer. *ecancermedicalscience*, 15.
- Elias, A., Burris, H., Patel, M., Schwartzberg, L., Richer, J., Kavalarchik, E., Stopatschinskaja, S., Gibbons, J., Markova, D., & Steinberg, J. (2016). Abstract P1-16-05: MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer. In: AACR.
- Eroles, P., Bosch, A., Pérez-Fidalgo, J. A., & Lluch, A. (2012). Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. *Cancer treatment reviews*, 38(6), 698-707.
- Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., & Guy, R. K. (2007). A surface on the androgen receptor that allosterically regulates coactivator binding. *Proceedings of the National Academy of Sciences*, 104(41), 16074-16079.
- Ferraldeschi, R., Welti, J., Powers, M. V., Yuan, W., Smyth, T., Seed, G., Riisnaes, R., Hedayat, S., Wang, H., & Crespo, M. (2016). Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. *Cancer research*, 76(9), 2731-2742.
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., & Fowst, C. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Research*, 11(5), 1-13.
- Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., & Kuss, I. (2019). Darolutamide in nonmetastatic, castration-resistant prostate cancer. *New England Journal of Medicine*, 380(13), 1235-1246.
- Franco, Y. L., Vaidya, T. R., & Ait-Oudhia, S. (2018). Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. *Breast Cancer: Targets and Therapy*, 10, 131.
- Friedland, J. C., Smith, D. L., Sang, J., Acquaviva, J., He, S., Zhang, C., & Proia, D. A. (2014). Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. *Investigational new drugs*, 32(1), 14-24.

- Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., & Pryer, N. K. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Molecular cancer therapeutics*, 3(11), 1427-1438.
- Gao, W. (2010). Androgen receptor as a therapeutic target. *Advanced drug delivery reviews*, 62(13), 1277-1284.
- Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. *Cancer discovery*, 9(2), 176-198.
- Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., & Del Mastro, L. (2018). Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. *Cancer treatment reviews*, 68, 102-110.
- Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A., Fasola, G., & Puglisi, F. (2015). Pattern of metastasis and outcome in patients with breast cancer. *Clinical & experimental metastasis*, 32(2), 125-133.
- Gomari, M. M., Farsimadan, M., Rostami, N., mahmoudi, Z., Fadaie, M., Farhani, I., & Tarighi, P. (2021). CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations. *Mutation Research/Reviews in Mutation Research*, 787, 108374. <https://doi.org/https://doi.org/10.1016/j.mrrev.2021.108374>
- Gong, Y., Ji, P., Yang, Y.-S., Xie, S., Yu, T.-J., Xiao, Y., Jin, M.-L., Ma, D., Guo, L.-W., & Pei, Y.-C. (2021). Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. *Cell Metabolism*, 33(1), 51-64. e59.
- Gottlieb, B., Beitel, L. K., Nadarajah, A., Paliouras, M., & Trifiro, M. (2012). The androgen receptor gene mutations database: 2012 update. *Human mutation*, 33(5), 887-894.
- Gucalp, A., Proverbs-Singh, T. A., Corben, A., Moynahan, M. E., Patil, S., Boyle, L. A., Hudis, C. A., & Traina, T. A. (2016). Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC). In: American Society of Clinical Oncology.
- Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., & Forero, A. (2013). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. *Clinical Cancer Research*, 19(19), 5505-5512.
- Gucalp, A., Tolaney, S. M., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K. L., Rugo, H. S., Nabell, L., & Forero-Torres, A. (2012). Targeting the androgen receptor (AR) in women with AR+ ER-/PR-metastatic breast cancer (MBC). In: American Society of Clinical Oncology.
- Gucalp, A., & Traina, T. A. (2016). Targeting the androgen receptor in triple-negative breast cancer. *Current problems in cancer*, 40(2-4), 141-150.
- Gucalp, A., & Traina, T. A. (2017). The androgen receptor: is it a promising target? *Annals of surgical oncology*, 24(10), 2876-2880.
- Gupta, S., Gupta, P. K., Dharanivasan, G., & Verma, R. S. (2017). Current prospects and challenges of nanomedicine delivery in prostate cancer therapy. *Nanomedicine*, 12(23), 2675-2692.
- Gupta, S., Nordquist, L. T., Fleming, M. T., Berry, W. R., Zhang, J., Ervin, S. L., Eisner, J. R., Baskin-Bey, E. S., & Shore, N. D. (2018). Phase I study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in men with castration-resistant prostate cancer. *Clinical Cancer Research*, 24(21), 5225-5232.

- Haelens, A., Tanner, T., Denayer, S., Callewaert, L., & Claessens, F. (2007). The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. *Cancer research*, 67(9), 4514-4523.
- Helsen, C., Van den Broeck, T., Voet, A., Prekovic, S., Van Poppel, H., Joniau, S., & Claessens, F. (2014). Androgen receptor antagonists for prostate cancer therapy. *Endocrine-related cancer*, 21(4), T105-T118.
- Hill, B. S., Sarnella, A., Capasso, D., Comegna, D., Del Gatto, A., Gramanzini, M., Albanese, S., Saviano, M., Zaccaro, L., & Zannetti, A. (2019). Therapeutic potential of a novel  $\alpha\beta3$  antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type. *Cancers*, 11(2), 139.
- Howard, F. M., & Olopade, O. I. (2021). Epidemiology of triple-negative breast cancer: a review. *The Cancer Journal*, 27(1), 8-16.
- Huang, C.-C. F., Lingadahalli, S., Morova, T., Ozturan, D., Hu, E., Yu, I. P. L., Linder, S., Hoogstraat, M., Stelloo, S., & Sar, F. (2021). Functional mapping of androgen receptor enhancer activity. *Genome biology*, 22(1), 1-26.
- Hwang, S.-Y., Park, S., & Kwon, Y. (2019). Recent therapeutic trends and promising targets in triple negative breast cancer. *Pharmacology & therapeutics*, 199, 30-57.
- Isaacsson Velho, P., Tofani Sant'Anna, P., Pereira da Silva, R. F., Dal Ponte Ferreira, R., & Venero, F. C. (2021). The development of apalutamide for the treatment of prostate cancer. *Expert Opinion on Drug Discovery*, 16(3), 217-226.
- Ismail, F. F., Meah, N., de Carvalho, L. T., Bhojrul, B., Wall, D., & Sinclair, R. (2020). Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients. *Journal of the American Academy of Dermatology*, 83(5), 1478-1479.
- Jhan, J.-R., & Andrechek, E. R. (2017). Triple-negative breast cancer and the potential for targeted therapy. *Pharmacogenomics*, 18(17), 1595-1609.
- Jiang, Y.-Z., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W.-J., Ma, D., Ding, J., Zhu, X., & Zou, J. (2021). Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. *Cell research*, 31(2), 178-186.
- Jin, C., Wang, K., Oppong-Gyebi, A., & Hu, J. (2020). Application of nanotechnology in cancer diagnosis and therapy-a mini-review. *International Journal of Medical Sciences*, 17(18), 2964.
- Karangadan, S., Patil, A. G., & Andola, S. K. (2016). Immunohistochemical characterization of molecular classification of breast carcinoma and its relation with Ki-67. *Clinical Cancer Investigation Journal*, 5(5), 430.
- Kawamura, N., Nimura, K., Saga, K., Ishibashi, A., Kitamura, K., Nagano, H., Yoshikawa, Y., Ishida, K., Nonomura, N., & Arisawa, M. (2019). SF3B2-mediated RNA splicing drives human prostate cancer progression. *Cancer research*, 79(20), 5204-5217.
- Kim, H., Samuel, S. L., Zhai, G., Rana, S., Taylor, M., Umphrey, H. R., Oelschlager, D. K., Buchsbaum, D. J., & Zinn, K. R. (2014). Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. *Cancer biology & therapy*, 15(8), 1053-1060.
- Kim, W., & Ryan, C. J. (2012). Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. *Current treatment options in oncology*, 13(2), 189-200.
- Koboldt, D., Fulton, R., McLellan, M., Schmidt, H., Kalicki-Veizer, J., McMichael, J., Fulton, L., Dooling, D., Ding, L., & Mardis, E. (2012). Comprehensive molecular portraits of human breast tumours. *Nature*, 490(7418), 61-70.
- Kounatidou, E., Nakjang, S., McCracken, S. R. C., Dehm, S. M., Robson, C. N., Jones, D., & Gaughan, L. (2019). A novel CRISPR-engineered prostate cancer cell line defines the

- AR-V transcriptome and identifies PARP inhibitor sensitivities. *Nucleic acids research*, 47(11), 5634-5647.
- Laufer, M., Sinibaldi, V. J., Carducci, M. A., & Eisenberger, M. A. (1999). Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. *Urology*, 54(4), 745.
- Lebert, J., Lester, R., Powell, E., Seal, M., & McCarthy, J. (2018). Advances in the systemic treatment of triple-negative breast cancer. *Current oncology*, 25(s1), 142-150.
- Lee, J. B., Zhang, K., Tam, Y. Y. C., Quick, J., Tam, Y. K., Lin, P. J., Chen, S., Liu, Y., Nair, J. K., & Zlatev, I. (2016). A Glu-urea-Lys ligand-conjugated lipid nanoparticle/siRNA system inhibits androgen receptor expression in vivo. *Molecular Therapy-Nucleic Acids*, 5, e348.
- Lee, J. B., Zhang, K., Tam, Y. Y. C., Tam, Y. K., Belliveau, N. M., Sung, V. Y., Lin, P. J., LeBlanc, E., Ciufolini, M. A., & Rennie, P. S. (2012). Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. *International Journal of Cancer*, 131(5), E781-E790.
- Lehmann, B. D., Abramson, V. G., Sanders, M. E., Mayer, E. L., Haddad, T. C., Nanda, R., Van Poznak, C., Storniolo, A. M., Nangia, J. R., & Gonzalez-Ericsson, P. I. (2020). TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. *Clinical Cancer Research*, 26(9), 2111-2123.
- Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *The Journal of clinical investigation*, 121(7), 2750-2767.
- Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., & Arteaga, C. L. (2014). PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. *Breast Cancer Research*, 16(4), 1-14.
- Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016). Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS one*, 11(6), e0157368.
- Li, J., Fu, J., Toumazou, C., Yoon, H.-G., & Wong, J. (2006). A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. *Molecular endocrinology*, 20(4), 776-785.
- Liu, T., Sun, B., Zhao, X., Zhao, X., Sun, T., Gu, Q., Yao, Z., Dong, X., Zhao, N., & Liu, N. (2013). CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. *Oncogene*, 32(5), 544-553.
- Liu, Y.-R., Jiang, Y.-Z., Xu, X.-E., Yu, K.-D., Jin, X., Hu, X., Zuo, W.-J., Hao, S., Wu, J., & Liu, G.-Y. (2016). Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. *Breast Cancer Research*, 18(1), 1-10.
- Liu, Y. X., Zhang, K. J., & Tang, L. L. (2018). Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study. *Oncology letters*, 15(6), 10008-10016.
- Lokeshwar, S. D., Klaassen, Z., & Saad, F. (2021). Treatment and trials in non-metastatic castration-resistant prostate cancer. *Nature Reviews Urology*, 1-10.
- LoRusso, P., Hamilton, E., Ma, C., Vidula, N., Bagley, R. G., Troy, S., Annett, M., Yu, Z., Conlan, M. G., & Weise, A. (2022). A First-in-Human Phase 1 Study of a Novel



- Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2-Metastatic Breast Cancer. *Clinical breast cancer*, 22(1), 67-77.
- Lyase, C. Androgen Receptor Inhibitor Treatment with Seviteronel Trial (INO-VT-464-006; NCT02580448-CLARITY-01), 2015. In.
- Lyons, T., Gucalp, A., Arumov, A., Patil, S., Edelweiss, M., Gorsky, M., Troso-Sandoval, T. A., Bromberg, J., Sanford, R. A., & Iyengar, N. M. (2018). Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. In: American Society of Clinical Oncology.
- Mahmoudi Gomari, M., Rostami, N., Ghodrati, A., Hernandez, Y., Fadaie, M., Sadegh Eslami, S., & Tarighi, P. (2021). Implementation of docking, molecular dynamics and free energy to investigate drug potency of novel BCR-ABL315I inhibitors as an alternative to ponatinib. *Computational Toxicology*, 20, 100180. <https://doi.org/https://doi.org/10.1016/j.comtox.2021.100180>
- Markham, A., & Duggan, S. (2019). Darolutamide: first approval. *Drugs*, 79(16), 1813-1818.
- Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., & Hortobagyi, G. N. (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clinical Cancer Research*, 19(19), 5533-5540.
- McCann, K. E., Hurvitz, S. A., & McAndrew, N. (2019). Advances in targeted therapies for triple-negative breast cancer. *Drugs*, 79(11), 1217-1230.
- McNamara, K. M., Yoda, T., Takagi, K., Miki, Y., Suzuki, T., & Sasano, H. (2013). Androgen receptor in triple negative breast cancer. *The Journal of steroid biochemistry and molecular biology*, 133, 66-76.
- Meakin, A., & Clifton, V. (2019). understanding the role of androgens and placental AR variants: insight into steroid-dependent fetal-placental growth and development. *Placenta*, 84, 63-68.
- Michmerhuizen, A. R., Chandler, B., Olsen, E., Wilder-Romans, K., Moubadder, L., Liu, M., Pesch, A. M., Zhang, A., Ritter, C., & Ward, S. T. (2020). Seviteronel, a novel CYP17 lyase inhibitor and androgen receptor antagonist, radiosensitizes AR-positive triple negative breast cancer cells. *Frontiers in endocrinology*, 11, 35.
- Mina, A., Yoder, R., & Sharma, P. (2017). Targeting the androgen receptor in triple-negative breast cancer: current perspectives. *OncoTargets and therapy*, 10, 4675.
- Misra, R., Acharya, S., & Sahoo, S. K. (2010). Cancer nanotechnology: application of nanotechnology in cancer therapy. *Drug discovery today*, 15(19-20), 842-850.
- Mohler, M. L., Coss, C. C., Duke III, C. B., Patil, S. A., Miller, D. D., & Dalton, J. T. (2012). Androgen receptor antagonists: a patent review (2008–2011). *Expert opinion on therapeutic patents*, 22(5), 541-565.
- Mohler, M. L., Sikdar, A., Ponnusamy, S., Hwang, D.-J., He, Y., Miller, D. D., & Narayanan, R. (2021). An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. *International journal of molecular sciences*, 22(4), 2124.
- Moilanen, A., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Tormakangas, O., & Kallio, P. (2013). ODM-201-new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. *European Journal of Cancer*,
- Monaghan, A. E., & McEwan, I. J. (2016). A sting in the tail: the N-terminal domain of the androgen receptor as a drug target. *Asian journal of andrology*, 18(5), 687.
- Moore, N. L., Buchanan, G., Harris, J. M., Selth, L. A., Bianco-Miotto, T., Hanson, A. R., Birrell, S. N., Butler, L. M., Hickey, T. E., & Tilley, W. D. (2012). An androgen

- receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. *Endocrine related cancer*, 19(4), 599.
- NAJAFI, S., EBRAHIMI, M., HASHEMI, E., ALAVI, N., OLFATBAKHS, A., HAGHIGHAT, S., & TAFAZZOLI, H. (2014). Whether adding GnRH analogs to Tamoxifen in breast cancer treatment aggravates menopause symptoms or not?
- Narayanan, R. (2020). Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. *Asian Journal of Urology*.
- Narayanan, R., Ahn, S., Cheney, M. D., Yepuru, M., Miller, D. D., Steiner, M. S., & Dalton, J. T. (2014). Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial: mesenchymal stem cell signaling. *PloS one*, 9(7), e103202.
- Nazari, A., Lopez-Valcarcel, B. G., & Najafi, S. (2021). Preferences of Patients With HR+ and HER2- Breast Cancer Regarding Hormonal and Targeted Therapies in the First Line of Their Metastatic Stage: A Discrete Choice Experiment. *Value in Health Regional Issues*, 25, 7-14.
- Negro-Vilar, A. (1999). Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. *The Journal of Clinical Endocrinology & Metabolism*, 84(10), 3459-3462.
- Nguyen, M. M., Dincer, Z., Wade, J. R., Alur, M., Michalak, M., DeFranco, D. B., & Wang, Z. (2009). Cytoplasmic localization of the androgen receptor is independent of calreticulin. *Molecular and cellular endocrinology*, 302(1), 65-72.
- Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., & Bhargava, R. (2010). Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. *Modern Pathology*, 23(2), 205-212.
- Nigam, A. (2013). Breast cancer stem cells, pathways and therapeutic perspectives 2011. *Indian Journal of Surgery*, 75(3), 170-180.
- Norman, A. W., Mizwicki, M. T., & Norman, D. P. (2004). Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. *Nature reviews Drug discovery*, 3(1), 27-41.
- Norris, J. D., Ellison, S. J., Baker, J. G., Stagg, D. B., Wardell, S. E., Park, S., Alley, H. M., Baldi, R. M., Yllanes, A., & Andreano, K. J. (2017). Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. *The Journal of clinical investigation*, 127(6), 2326-2338.
- O'Connor, C. J., Chen, T., González, I., Cao, D., & Peng, Y. (2018). Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker. *Biomarkers in medicine*, 12(7), 813-820.
- Ornstein, M. C., Stephenson, A. J., Elson, P., Tyler, A. J., Profusek, P., Grivas, P., Rini, B. I., Klein, E. A., & Garcia, J. A. (2016). Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). In: American Society of Clinical Oncology.
- Osguthorpe, D., & Hagler, A. (2011). Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. *Biochemistry*, 50(19), 4105-4113.
- Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016). Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. *NPJ breast cancer*, 2(1), 1-11.
- Park, S., Koo, J., Kim, M., Park, H., Lee, J., Kim, S., Park, B.-W., & Lee, K. (2011). Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. *Annals of Oncology*, 22(8), 1755-1762.

- Perrault, D. J., Logan, D. M., Stewart, D. J., Bramwell, V. H., Paterson, A. H., & Eisenhauer, E. A. (1988). Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. *Investigational new drugs*, 6(3), 207-210.
- Pietri, E., Conteduca, V., Andreis, D., Massa, I., Melegari, E., Sarti, S., Ceconetto, L., Schirone, A., Bravaccini, S., & Serra, P. (2016). Androgen receptor signaling pathways as a target for breast cancer treatment. *Endocr Relat Cancer*, 23(10), R485-R498.
- Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Research*, 12(5), 1-18.
- Proia, D. A., Zhang, C., Sequeira, M., Jimenez, J.-P., He, S., Spector, N., Shapiro, G. I., Tolaney, S., Nagai, M., & Acquaviva, J. (2014). Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. *Clinical Cancer Research*, 20(2), 413-424.
- Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019). STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. *Journal of Experimental & Clinical Cancer Research*, 38(1), 1-16.
- Qiu, P., Guo, Q., Yao, Q., Chen, J., & Lin, J. (2021). Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer. *PloS one*, 16(11), e0254283.
- Radaeva, M., Ban, F., Zhang, F., LeBlanc, E., Lallous, N., Rennie, P. S., Gleave, M. E., & Cherkasov, A. (2021). Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. *International journal of molecular sciences*, 22(5), 2493.
- Rafferty, S. W., Eisner, J. R., Moore, W. R., Schotzinger, R. J., & Hoekstra, W. J. (2014). Highly-selective 4-(1, 2, 3-triazole)-based P450c17a 17, 20-lyase inhibitors. *Bioorganic & medicinal chemistry letters*, 24(11), 2444-2447.
- Rahim, B., & O'Regan, R. (2017). AR signaling in breast cancer. *Cancers*, 9(3), 21.
- Rampurwala, M., Wisinski, K. B., & O'Regan, R. (2016). Role of the androgen receptor in triple-negative breast cancer. *Clinical advances in hematology & oncology: H&O*, 14(3), 186.
- Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: global trends, etiology and risk factors. *World journal of oncology*, 10(1), 10.
- Reid, J., Betney, R., Watt, K., & McEwan, I. J. (2003). The androgen receptor transactivation domain: the interplay between protein conformation and protein-protein interactions. *Biochemical Society Transactions*, 31(5), 1042-1046.
- Robles, A. J., Cai, S., Cichewicz, R. H., & Mooberry, S. L. (2016). Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. *Breast cancer research and treatment*, 157(3), 475-488.
- Rostami, N., & Davarnejad, R. (2021). Characterization of folic acid-functionalized PLA-PEG nanomicelle to deliver Letrozole: A nanoinformatics study. *IET Nanobiotechnol.*
- Safarpour, D., Pakneshan, S., & Tavassoli, F. A. (2014). Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? *American journal of cancer research*, 4(4), 353.
- Saranyutanon, S., Srivastava, S. K., Pai, S., Singh, S., & Singh, A. P. (2020). Therapies targeted to androgen receptor signaling axis in prostate cancer: Progress, challenges, and hope. *Cancers*, 12(1), 51.
- Shah, P. D., Gucalp, A., & Traina, T. A. (2013). The role of the androgen receptor in triple-negative breast cancer. *Women's health*, 9(4), 351-360.

- Slovin, S., Hussain, S., Saad, F., Garcia, J., Picus, J., Ferraldeschi, R., Crespo, M., Flohr, P., Riisnaes, R., & Lin, C. (2019). Pharmacodynamic and clinical results from a phase I/II study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer. *Clinical Cancer Research*, 25(15), 4624-4633.
- Smith, M. R., Antonarakis, E. S., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., Alumkal, J. J., Higano, C. S., Maneval, E. C., & Bandekar, R. (2016). Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. *European urology*, 70(6), 963-970.
- Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., & Uemura, H. (2018). Apalutamide treatment and metastasis-free survival in prostate cancer. *New England Journal of Medicine*, 378(15), 1408-1418.
- Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W. (2019). Selective androgen receptor modulators: current knowledge and clinical applications. *Sexual medicine reviews*, 7(1), 84-94.
- Song, Y., Huang, R., Wu, S., Zheng, H., Guo, M., Fu, L., & Yu, S. (2021). Diagnostic and prognostic role of NR3C4 in breast cancer through a genomic network understanding. *Pathology-Research and Practice*, 217, 153310.
- Speers, C., Zhao, S. G., Chandler, B., Liu, M., Wilder-Romans, K., Olsen, E., Nyati, S., Ritter, C., Alluri, P. G., & Kothari, V. (2017). Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. *NPJ breast cancer*, 3(1), 1-10.
- Spiegelberg, D., Abramenkova, A., Mortensen, A. C. L., Lundsten, S., Nestor, M., & Stenerlöv, B. (2020). The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach. *Scientific reports*, 10(1), 1-11.
- Sridhar, N., Glisch, C., Jawa, Z., Chaudhary, L. N., Kamaraju, S., Burfeind, J., Charlson, J., Chitambar, C. R., Jorns, J. M., & Cheng, Y. C. (2022). Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study. *Journal of Cancer*, 13(8), 2472.
- Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016). Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. *Oncotarget*, 7(50), 82889.
- Thakur, V., & Kutty, R. V. (2019). Recent advances in nanotheranostics for triple negative breast cancer treatment. *Journal of Experimental & Clinical Cancer Research*, 38(1), 1-22.
- Tietz, K. T., & Dehm, S. M. (2020). Androgen receptor variants: RNA-based mechanisms and therapeutic targets. *Human molecular genetics*, 29(R1), R19-R26.
- Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O'Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., & Kelly, C. (2018). Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. *Journal of clinical oncology*, 36(9), 884.
- Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., & Gianni, L. (2015). Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). In: American Society of Clinical Oncology.
- Traina, T. A., Yardley, D., Patel, M., Schwartzberg, L., Elias, A., Gucalp, A., Peterson, A. C., Hannah, A., Gibbons, J., & Khondker, Z. (2013). Abstract PD3-6: A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer. In: AACR.

- Tsang, J., & Tse, G. M. (2020). Molecular classification of breast cancer. *Advances in anatomic pathology*, 27(1), 27-35.
- Wahdan-Alaswad, R., Harrell, J. C., Fan, Z., Edgerton, S. M., Liu, B., & Thor, A. D. (2016). Metformin attenuates transforming growth factor beta (TGF- $\beta$ ) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. *Cell cycle*, 15(8), 1046-1059.
- Wang, R., Xu, K., Gao, F., Huang, J., & Guan, X. (2021). Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 188590.
- Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008). Application of nanotechnology in cancer therapy and imaging. *CA: a cancer journal for clinicians*, 58(2), 97-110.
- Ware, K. E., Garcia-Blanco, M. A., Armstrong, A. J., & Dehm, S. M. (2014). Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. *Endocrine-related cancer*, 21(4), T87-T103.
- Wei, C., Wang, F., Liu, W., Zhao, W., Yang, Y., Li, K., Xiao, L., & Shen, J. (2018). CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. *Molecular medicine reports*, 17(2), 2901-2906.
- Weigman, V. J., Chao, H.-H., Shabalin, A. A., He, X., Parker, J. S., Nordgard, S. H., Grushko, T., Huo, D., Nwachukwu, C., & Nobel, A. (2012). Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. *Breast cancer research and treatment*, 133(3), 865-880.
- Wein, L., & Loi, S. (2017). Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). *The Breast*, 34, S27-S30.
- Wesolowski, R., Brufsky, A., Chambers, M., Bhattacharya, S., Lustberg, M., VanDeusen, J., Sardesai, S., Williams, N., Noonan, A., & Phelps, M. (2019). Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173). *Annals of Oncology*, 30, v126.
- WHO. (2021). *Breast cancer*; Accessed March 26. WHO. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- Witzel, I., Loibl, S., Wirtz, R., Fasching, P. A., Denkert, C., Weber, K., Lück, H.-J., Huober, J., Karn, T., & Mackelenbergh, M. v. (2019). Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. *British journal of cancer*, 121(12), 1009-1015.
- Xiang, L., Gilkes, D. M., Chaturvedi, P., Luo, W., Hu, H., Takano, N., Liang, H., & Semenza, G. L. (2014). Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. *Journal of molecular medicine*, 92(2), 151-164.
- Yamamoto, Y., Lin, P. J., Beraldi, E., Zhang, F., Kawai, Y., Leong, J., Katsumi, H., Fazli, L., Fraser, R., & Cullis, P. R. (2015). siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer Lipid Nanoparticle siRNA Systems in CRPC. *Clinical Cancer Research*, 21(21), 4845-4855.
- Yong, L., Thet, Z., & Zhu, Y. (2017). Genetic editing of the androgen receptor contributes to impaired male courtship behavior in zebrafish. *J Exp Biol*, 220(Pt 17), 3017-3021. <https://doi.org/10.1242/jeb.161596>
- Yu, J., Zhou, P., Hu, M., Yang, L., Yan, G., Xu, R., Deng, Y., Li, X., & Chen, Y. (2019). Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. *European Journal of Medicinal Chemistry*, 182, 111608.

- Yuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Gillece, J. D., Folkerts, M., & Reining, L. (2021). A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. *The Oncologist*, 26(2), 99-e217.
- Zhang, X., Liu, N., Shao, Z., Qiu, H., Yao, H., Ji, J., Wang, J., Lu, W., Chen, R. C., & Zhang, L. (2017). Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. *Nanomedicine: Nanotechnology, Biology and Medicine*, 13(4), 1309-1321.
- Zhao, T., & He, G. (1988). A phase II clinical trial of flutamide in the treatment of advanced breast cancer. *Tumori Journal*, 74(1), 53-56.
- Zhao, Y., Goto, K., Saitoh, M., Yanase, T., Nomura, M., Okabe, T., Takayanagi, R., & Nawata, H. (2002). Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment: Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor. *Journal of Biological Chemistry*, 277(33), 30031-30039.
- Zhu, A., Li, Y., Song, W., Xu, Y., Yang, F., Zhang, W., Yin, Y., & Guan, X. (2016). Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer. *Cell Physiol Biochem*, 38(3), 1003-1014. <https://doi.org/10.1159/000443052>
- Zimmer, A. S. (2021). Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic. *The Cancer Journal*, 27(1), 76-82.

## Figure Legends

**Figure 1.** a: incidence rate. BC is classified as Luminal A, Luminal B, HER2 positive and triple-negative based on the status of ER, PR, HER2; b and c: TNBC classification by Abramson et al., 2015; Lehmann et al., 2011 and Lehmann et al., 2016 respectively.

**Figure 2.** Schematic representation of AR gene and AR protein. Top, the AR gene is found on the Xq11–12 chromosome. Middle, eight exons (exons 1–8) are separated by seven introns in the AR protein. The lower part of the figure shows the communication between the exon and AR protein domains: exon 1 coding for N-terminal region (AR-NTD), exons 2 and 3 coding for DNA binding domain (AR-DBD), The 5' area of exon 4 encoded for a hinge domain which contains the nuclear localization signal, the 3' region of exon 4–8 coding for the ligand-binding domain (AR-LBD).

**Figure 3.** Amino acid sequence (a), and 3D structure and its inhibitors (b) of AR. Abbreviations: AF-1 (ligand-independent activation function 1), AF-2 (ligand-independent activation function 2), DBD (DNA binding domain), LBD (ligand-binding domain), and NTD (N-terminal domain).

**Figure 4.** Representation mechanisms of blockade of AR in TNBC subtype. The enzyme CYP17A1 is responsible for converting the androgen precursors to DHEA, whereas HSD3 $\beta$ 1 performs DHEA conversion to AD, AKR1C3 performs AD conversion to testosterone. Abiraterone acetate is an inhibitor of CYP17. Also, Seviteronel (VT-464) is a CYP17A1 inhibitor. Seviteronel directly inhibits AR activity in the pre-clinical models. Following cytoplasm entrance, testosterone was reduced to DHT using 5 $\alpha$ -reductase. Heat shock proteins release AR, and it is activated through DHT binding. Enzalutamide and Bicalutamide are AR antagonists binding to the AR ligand site, preventing ligands from binding to AR. Enzalutamide inhibits AR nucleus translocation and prevents AR-mediated transcription.

**Figure 5.** Mechanism of CRISPR activity to target AR in BC and PC. AR gene expression can be changed in two ways using the CRISPR system. 1: knocked out; expression of AR gene is blocked in this manner. As a result, the cells are entirely depleted of AR, effective in inhibiting cancer cell growth and proliferation, also show insensitivity to androgens. 2: Changing in splicing and expression; by editing the genome.

**Table1.** Molecular classification of breast cancer

	ER		PR		HER
Luminal A	+	and/or	+		-
Luminal B	+	and/or	+/- <sup>a</sup>	or	-
Luminal B	+	and/or	+/- <sup>b</sup>	or	+
HER+	-		-		+
TNBC or basal-like	-		-		-

a (PR<20% + Ki 67>14%)

b (Any PR + any Ki 67)



**Table 2.** Subtypes of TNBC based on gene expression

Subtypes	Characteristic
Basal-Like 1	<ul style="list-style-type: none"> <li>– Expression of cell cycle, proliferation and DNA repair genes</li> <li>– High expression of ki-67 gene</li> </ul>
Basal-Like 2	<ul style="list-style-type: none"> <li>– Enriched in growth factor signaling pathway (EGFR, MET, NGF and IGF-1R)</li> <li>– Glycolysis and gluconeogenesis</li> <li>– Expression of myoepithelial</li> </ul>
Immunomodulatory	<ul style="list-style-type: none"> <li>– Expression of gene involved in immune cell processes (CTLA4, IL7, IL2, B cell, T cell and NK cells)</li> <li>– Cytokine signaling</li> </ul>
Mesenchymal	<ul style="list-style-type: none"> <li>– High expression gene of cell motility and extracellular matrix</li> <li>– Cell differentiation</li> <li>– IGF</li> </ul>
Mesenchymal Stem-Like	<ul style="list-style-type: none"> <li>– Similar to M with enrichment in genes involved in cell motility and extracellular matrix</li> <li>– High expression of gene involved in stem cells pathway</li> <li>– JAK-STAT3 activation</li> </ul>
Luminal Androgen Receptor	<ul style="list-style-type: none"> <li>– Androgen receptor signaling</li> <li>– High expression of gene involved in hormonally regulated signaling (steroid synthesis and Metabolism)</li> </ul>

**Table 3.** Current clinical trials targeting the AR-signaling pathway in prostate cancer.

Agent	Clinicaltrials.gov Identifier	Phase	Mechanism of Action	Objectives	Ref
Hydroxyflutamide	NCT02341404	II	Antiandrogen	Characterize and quantify the histopathological changes in the surgical specimens	( <a href="#">Gupta et al., 2017</a> )
Enzalutamide	NCT01927627	II	Antiandrogen	Evaluating the clinical activity and safety of Enzalutamide in men with high-risk prostate cancer	( <a href="#">Ornstein et al., 2016</a> )
Apalutamide (ARN-509)	NCT02770391	II	Antiandrogen	Determine if neo-adjuvant leuprolide and ARN-509 have different effects on dihydrotestosterone (DHT) levels in benign prostate tissue. Evaluate the differential effect of neoadjuvant leuprolide and ARN-509 on other androgens	( <a href="#">Al-Salama, 2018</a> ; <a href="#">Smith et al., 2016</a> )
Bicalutamide	NCT00846976	III	Antiandrogen	Check the health of patients receiving a 200 mg daily dose of CASODEX.	( <a href="#">Laufer et al., 1999</a> ; <a href="#">Osguthorpe &amp; Hagler, 2011</a> )
Flutamide	NCT00006214	II	Antiandrogen	Determine the ability of flutamide to reduce the incidence of prostate cancer in patients with high grade prostatic intraepithelial neoplasia	( <a href="#">Eisenberger et al., 1998</a> )
Darolutamide	NCT04157088	III	Antiandrogen	Compare the effects of drug darolutamide and drug Enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer	( <a href="#">Fizazi et al., 2019</a> )
Galeterone	NCT01709734	II	Antiandrogen	Two-part trial to evaluate the safety and efficacy of galeterone in castration-resistant prostate cancer (CRPC) patients	( <a href="#">Bastos &amp; Antonarakis, 2016</a> )
Nilutamide	NCT00918385	II	Antiandrogen	Determine the clinical impact of using a patient-specific genomic expression signature of androgen receptor (AR) activity to determine therapy for patients with castration-resistant metastatic prostate cancer (CRPC).	( <a href="#">Dole &amp; Holdsworth, 1997</a> )

**Table 4.** Recently completed and recruiting clinical trials targeting androgen, CDK4/6 and PI3K signaling in TNBC

Responsible Party	Listed Location Countries	Ref
Zhong-yu Yuan, Sun Yat-sen University	China	<a href="#">(Hwang et al., 2019)</a>
Memorial Sloan Kettering Cancer Center	United States	<a href="#">(Gucalp et al., 2013)</a>
Xiaoxiang Guan, Jinling Hospital, China	Not Provided	<a href="#">(Gucalp et al., 2013)</a>
Pfizer	Canada, Italy, Spain, United Kingdom, United States	<a href="#">(Traina et al., 2015)</a>
Memorial Sloan Kettering Cancer Centre	United States	<a href="#">(Lyons et al., 2018)</a>
M.D. Anderson Cancer Center	United States	<a href="#">(Gerratana et al., 2018)</a>
Cancer Research UK	United Kingdom	<a href="#">(Gerratana et al., 2018)</a>
UNICANCER	France	<a href="#">(Bonnefai et al., 2016)</a>
Innocrin Pharmaceutical	United States	<a href="#">(Bardia et al., 2018; Michmerhuizen et al., 2020)</a>
Innocrin Pharmaceutical	United States	<a href="#">(Michmerhuizen et al., 2020)</a>
Ruth O'Regan, M.D., Big Ten Cancer Research Consortium	United States	<a href="#">(Wang et al., 2021)</a>
Memorial Sloan Kettering Cancer Center	United States	<a href="#">(Gucalp et al., 2016; Wang et al., 2021)</a>
Vandana Abramson, Vanderbilt-Ingram Cancer Center	United States	<a href="#">(Lehmann et al., 2020)</a>
AstraZeneca	Canada, Spain, United Kingdom, United States	<a href="#">(Lebert et al., 2018)</a>
M.D. Anderson Cancer Center	United States	<a href="#">(Garrido-Castro et al., 2019)</a>

**Table 4.** Continued




Recruitment Status	Trial design (Total N patients)	Year (start- Estimated Study Completion Date)
Recruiting	18 Years to 70 Years, Female (262)	December 2016- December 2020
Active, not recruiting	18 Years to 120 years, all (28)	May 2007- March 2021
Not yet Recruiting	Years, Female (60) 18 Years to 70	January 2017 -January 2015
Active, not recruiting	18 years and older, Female (118)	June 2013- April 2020
Active, not recruiting	18 years and older, Female (200)	April 2016- May 2021
Recruiting	18 years and older, all (37)	February 2016- September 2020
Completed	18 years and older, Female (77)	September 2008- June 2016
Active, not recruiting	18 years and older, Female (31)	April 2013- July 2015
Completed	18 years and older, all (175)	October 2015- January 2019
Completed	18 years and older, all (175)	April 2014- September 2017
Active, not recruiting	18 years and older, all (11)	March 2017- September 2022
Active, not recruiting	18 years and older, Female (46)	November 2015- November 2022
Active, not recruiting	18 years and older, all (30)	May 2015- May 7, 2020
Completed	18 years and older, all (147)	June 2013- March 2019
Recruiting	18 years and older, all (28)	June 2017- December 2020


**Table 4.** Continued

Agent	Clinicaltrials.gov Identifier	Phase	Mechanism of Action	Study arm(s)
Bicalutamide	NCT03055312	III	AR inhibitor	Bicalutamide versus TPC (TX, GT or GC)
	NCT00468715	II	AR inhibitor	Bicalutamide
	NCT02353988	II	AR inhibitor	Bicalutamide versus Physician's Choice
Enzalutamide	NCT01889238	II	AR inhibitor	Enzalutamide
	NCT02750358	II	AR inhibitor	Enzalutamide
	NCT02689427	IIb	AR inhibitor + Antimicrotubule	Enzalutamide + paclitaxel
Abiraterone acetate	NCT00755885	II	CYP17 inhibitor	Abiraterone acetate
	NCT01842321	II	CYP17 inhibitor	Abiraterone Acetate + Prednisone
Seviteronel	NCT02580448	II	CYP17 inhibitor	Seviteronel
	NCT02130700	II	CYP17 inhibitor	Seviteronel
CDK4/6 + AR inhibition	NCT03090165	I/II	AR inhibitor + CDK 4/6 Inhibitor	Bicalutamide + Ribociclib
	NCT02605486	I/II	AR inhibitor + CDK 4/6 Inhibitor	Bicalutamide + Palbociclib
AR inhibitor + PI3K inhibitor	NCT02457910	Ib/II	AR inhibitor + PI3K inhibitor	Enzalutamide + Taselisib
	NCT01884285	I	AR inhibitor + PI3K inhibitor + mTOR inhibitor	AZD8186 + AZD2014 + Abiraterone
	NCT03207529	I	AR inhibitor + PI3K inhibitor	Enzalutamide + Alpelisib

# Fig. 1

Pharmrev Fast Forward. Published on 12 December 2022 as DOI 10.1124/pharmrev.122.000665 This article has not been copyedited and formatted. The final version may differ from this version.



**Fig. 2**

**Fig. 3**

**a**

AR-NTD (1-559)

AR-DBD (555-636)

Zinc finger (560-580 and 596-620)

Hinge (629-670)


AR-LBD (669-900)

```

1  MEVQLGLGRV YPRPPSKTYR GAFQNLFSV REVIQNPGR HPEAASAAPP GASLLLLQQQ QQQQQQQQQ QQQQQQQQQ
81  ETSPRQQQQ QGEDGSPQAH RRGPTGYLVL DEEQPSQPQ SALECHPERG CVPEPGAAVA ASKGLPQQLP APPDEDDSA
161 PSTLSLLGPT FPLSSCSAD LKDILSEAST MQLLQQQQE AVSEGSSSGR AREASGAPTS SKDNYLGGTS TISDNAKELC
241 KAVSVSMGLG VEALEHLSPG EQLRGDCMYA PLLGVPPAVR PTPCAPLAEC KGSLLDDSAG KSTEDTAEYS PFKGGYTKGL
321 EGESLGCSSG AAAGSSGTLE LPSTLSLYKS GALDEAAAYQ SRDYINFPLA LAGPPPPPP PHPHARIKLE NPLDYGSAWA
401 AAAAQCRYGD LASLHGAGAA GPGSGSPSAA ASSSWHTLFT AEEGQLYGPC GGGGGGGGGG GGGGGGGGGG GGGEAGAVAP
481 YGYTRPPQGL AGQESDFTAP DVWYPGGMVS RVPYSPTCV KSEMPWMDS YSGPYGDMRL ETARDHVLPI DYYFPQKTC
561 LICGDEASGC HYGALTCGSC KVFFKRAAEG KQKYL CASRN DCTIDKFRK NCPSCLRKC YEAGMTLGAR KLKKLGNLKL
641 QEEGEASSTT SPTEETTQKL TVSHIEGYEC QPIFLNVLEA IEPGVVCAGH DNNQPDSFAA LLSSLNELGE RQLVHVVKWA
721 KALPGFRNLH VDDQMAVIQY SWMGLMVFAM GWRSFNTVNS RMLYFAPDLV FNEYRMHKS R MYSQCVRMRH LSQEFGLQI
801 TPQEFMKA LLLFSIIPVD GLKNQKFFDE LRMNYIKELD RIIACKRKNP TCSRRFYQL TKLLDSVQPI ARELHQFTFD
881 LLIKSHMVSV DFPEMMAEII SVQVPKILSG KVKPIYFHTQ
  
```


Pharmrev Fast Forward. Published on 12 December 2022 as DOI 10.1124/pharmrev.122.000665 This article has not been copyedited and formatted. The final version may differ from this version.

**b**






**Fig. 4**




**Fig. 5**




Pharmrev Fast Forward, Published on 12 December 2022 as DOI:10.1124/pharmrev.122.000665 This article has not been certified and peer reviewed. The final version may differ from this version.

- Androgen-depleted**
- Insensitive to androgens
  - Cancer cell therapy
  - Inhibits the growth and proliferation of cancer cells

- Improve affinity to new drug
- Improve responsibility to new drug
- Reduce off-targeting



- Resistance to next generation drug therapy
- Resistance to Treatment with androgen deprivation
- Increase in metastasis, EMT and hormone-refractory prostate cancer(HRPC)
- In vivo promotes invasive adenocarcinoma



Downloaded from pharmrev.asphpubs.org at ASPET Journals on April 19, 2024